

BEST AVAILABLE COPY

Access DB#

76303

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: PATEL SUDHAKER Examiner #: 77018 Date: 9/23/02
 Art Unit: 1624 Phone Number 30 84709 Serial Number: 09895843
 Mail Box and Bldg/Room: CM14E17 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.


Title of Invention: COMPOUNDS TO TREAT ALZHEIMER'S DISEASE

Inventors (please provide full names):

JAMES P. Beck et al

Earliest Priority Filing Date: 6/30/2000

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



Need info @ compounds, compositions & method of treating ALZHEIMER'S Disease
 copy 1 claims enclosed

Point of Contact:
 Barb O'Brien
 Technical Information Specialist
 STIC CM1 6A05 308-4291

Need d of b b h l s h

(APLUS)
 THE
 PR

STAFF USE ONLY

Searcher: ASB
 Searcher Phone #: _____
 Searcher Location: _____
 Date Searcher Picked Up: _____
 Date Completed: 9-26-02
 Searcher Prep & Review Time: 90
 Clerical Prep Time: _____
 Online Time: 35

Type of Search

NA Sequence (#) _____
 AA Sequence (#) _____
 Structure (#) 2
 Bibliographic _____
 Litigation _____
 Fulltext _____
 Patent Family _____
 Other _____

Vendors and cost where applicable

STN 520
 Dialog _____
 Questel/Orbit _____
 Dr.Link _____
 Lexis/Nexis _____
 Sequence Systems _____
 WWW/Internet _____
 Other (specify) Chem Draw

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
 present
 NEWS 4 Jul 15 Data from 1960-1976 added to RDISCLOSURE
 NEWS 5 Jul 21 Identification of STN records implemented
 NEWS 6 Jul 21 Polymer class term count added to REGISTRY
 NEWS 7 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
 Right Truncation available
 NEWS 8 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
 August 1, 2003
 NEWS 9 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS 10 AUG 15 PATDPAFULL: one FREE connect hour, per account, in
 September 2003
 NEWS 11 AUG 15 PCTGEN: one FREE connect hour, per account, in
 September 2003
 NEWS 12 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in
 September 2003
 NEWS 13 AUG 15 TEMA: one FREE connect hour, per account, in
 September 2003
 NEWS 14 AUG 18 Data available for download as a PDF in RDISCLOSURE
 NEWS 15 AUG 18 Simultaneous left and right truncation added to PASCAL
 NEWS 16 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
 Truncation
 NEWS 17 AUG 18 Simultaneous left and right truncation added to ANABSTR
 NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
 MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:32:13 ON 20 SEP 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:32:24 ON 20 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2003 HIGHEST RN 588668-76-2

DICTIONARY FILE UPDATES: 18 SEP 2003 HIGHEST RN 588668-76-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNnote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09895843.1

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:32:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 298
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 12:32:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 103 TO ITERATE

100.0% PROCESSED 103 ITERATIONS
SEARCH TIME: 00.00.01

3 ANSWERS

L3 3 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
148.95	149.16

FULL ESTIMATED COST

FILE 'MARPAT' ENTERED AT 12:34:23 ON 20 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 15-VOL 139 ISS11) (20030912ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6605638 12 AUG 2003
DE 20300703 07 AUG 2003
EP 1335416 13 AUG 2003
JP 2003230397 19 AUG 2003
WO 2003068205 21 AUG 2003

Structure search limits have been raised. See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 12:34:32 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 925 TO ITERATE

100.0% PROCESSED 925 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.04

L4 2 SEA SSS FUL L1

=> d l4 fbib hitstr abs total
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'MARPAT'

The following are valid formats:

MSTR ----- All Markush structure(s) and related text information
MSTR(n) -- Markush structure(n) and related text information
IDE ----- AN and MSTR

ABS ----- AB
ALL ----- BIB, AB, IND, RE, and MSTR
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing Data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT, and FQHIT
SCAN ----- CC, SX, TI, ST, IT, and FQHIT (random display,
no answer numbers)
STD ----- BIB, IPC, and NCL (standard patent information)

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels

IBIB ----- BIB, indented with text labels
 IMAX ----- MAX, indented with text labels
 ISTD ----- STD, indented with text labels
 OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit text terms and the Markush
 structures containing the query structure
 FHIT ----- Fields containing the first hit text terms and the first
 Markush structures containing the query structure
 QHIT ----- Fields containing query focus hit text terms and the
 Markush structures containing the query structure
 FQHIT ----- Fields containing the first query focus hit text terms and
 the first Markush structures containing the query structure

To display a particular field or fields, enter the display field
 codes. For a list of the display field codes, enter "HELP DFIELDs"
 at an arrow prompt (=>). Examples of formats include: "TI";
 "TI,MSTR,ABS"; "BIB,ST"; "TI,IND"; "TI,SO". You may specify the
 format fields in any order and the information will be displayed
 in the same order as the format specification.

All of the formats (except for SAM, SCAN, FHIT, HIT, FQHIT, or QHIT) may
 be used with the DISPLAY ACC command to display the record for a
 specified Accession Number.

ENTER DISPLAY FORMAT (BIB):bib

L4 ANSWER 1 OF 2 MARPAT COPYRIGHT 2003 ACS on STN
 AN 136:102193 MARPAT
 TI Preparation of disubstituted amines for treating Alzheimer's disease
 IN Beck, James P.; Gailunas, Andrea; Hom, Roy; Jagodzinska, Barbara; John,
 Varghese; Maillaird, Michel
 PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
 SO PCT Int. Appl., 286 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002520	A2	20020110	WO 2001-US21000	20010702
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002143177	A1	20021003	US 2001-895843	20010629
	AU 2001073132	A5	20020114	AU 2001-73132	20010702
PRAI	US 2000-215323P		20000630		

US 2001-895843 20010629
 WO 2001-US21000 20010702

L4 ANSWER 2 OF 2 MARPAT COPYRIGHT 2003 ACS on STN
 AN 136:102192 MARPAT
 TI Preparation of disubstituted amines for treating Alzheimer's disease
 IN Beck, James P.; Gailunas, Andrea; Hom, Roy; Jagodzinska, Barbara; John, Varghese; Maillaird, Michel
 PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
 SO PCT Int. Appl., 286 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002518	A2	20020110	WO 2001-US20856	20010629
	WO 2002002518	A3	20020808		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001073094	A5	20020114	AU 2001-73094	20010629
	US 2002016320	A1	20020207	US 2001-896874	20010629
	US 2003096864	A1	20030522	US 2001-895871	20010629
PRAI	US 2000-215323P	20000630			
	WO 2001-US20856	20010629			

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
106.87	256.03

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:35:21 ON 20 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2003 VOL 139 ISS 13

FILE LAST UPDATED: 19 Sep 2003 (20030919/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L5 3 L3

=> d 13 fbib hitstr abs total

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> s 13

L6 3 L3

=> d 16 fbib hitstr abs total

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:376819 CAPLUS

DN 138:385173

TI Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease

IN Varghese, John; Maillard, Michel; Jagodzinska, Barbara; Beck, James P.; Gailunas, Andrea; Fang, Larry; Sealy, Jennifer; Tenbrink, Ruth; Freskos, John; Mickelson, John; Samala, Lakshman; Hom, Roy

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 1243 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040096	A2	20030515	WO 2002-US36072	20021108
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2001-337122PP	20011108
				US 2001-344086PP	20011228
				US 2002-345635PP	20020103
	WO 2003040096	A2	20030515	WO 2002-XA36072	20021108
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,			

NE, SN, TD, TG

US 2001-337122PP 20011108
 US 2001-344086PP 20011228
 US 2002-345635PP 20020103
 WO 2002-US36072A 20021108

PATENT FAMILY INFORMATION:

FAN 2003:412801

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040096	A2	20030515	WO 2002-XA36072	20021108
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2001-337122PP 20011108
 US 2001-344086PP 20011228
 US 2002-345635PP 20020103
 WO 2002-US36072A 20021108

WO 2003040096	A2	20030515	WO 2002-US36072	20021108
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2001-337122PP 20011108
 US 2001-344086PP 20011228
 US 2002-345635PP 20020103

OS MARPAT 138:385173

IT 527721-06-8P 527721-73-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease)

RN 527721-06-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[4-[(1-methyl-1H-imidazol-2-yl)methyl]-1-piperazinyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 527721-73-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[2-(hydroxyphenylmethyl)-4-methyl-1-piperazinyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl, haloalkyl, alkenyl, etc.; R3 = H, alkyl, haloalkyl, alkenyl, etc.; or R2 and R3 are taken together with the carbon to which they are attached to form a carbocycle of 3-7 carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of O, S, SO₂, (un)substituted NH; R4 = alkyl, haloalkyl, hydroxyalkyl, etc.; R5 = R6X (wherein X = CO, SO₂, (un)substituted CH₂; R6 = (un)substituted Ph, naphthyl, indanyl, etc.); R25 = H, alkyl, alkoxy, etc.] which have activity as inhibitors of .beta.-secretase and are therefore useful in treating a variety of disorders such as Alzheimer's disease, were prepd. E.g., a multi-step synthesis of (1S,2R)-II, starting from (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3,5-difluorophenyl)propanoic acid, was given. The compds. I showed IC₅₀ of < 20 .mu.M in cell free inhibition assay utilizing a synthetic APP substrate. This is a Part 1 of 1-2 series.

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:31410 CAPLUS

DN 136:102193

TI Preparation of disubstituted amines for treating Alzheimer's disease

IN Beck, James P.; Gailunas, Andrea; Hom, Roy; Jagodzinska, Barbara; John, Varghese; Maillaird, Michel

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002520	A2	20020110	WO 2001-US21000	20010702
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,			

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
 TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2000-215323PP 20000630
 US 2001-895843 A 20010629
 US 2001-895843 20010629
 US 2000-215323PP 20000630
 AU 2001-73132 20010702
 US 2000-215323PP 20000630
 US 2001-895843 A 20010629
 WO 2001-US21000W 20010702

PATENT FAMILY INFORMATION:

FAN 2002:31396

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002505	A2	20020110	WO 2001-US20852	20010629
WO 2002002505	A3	20020801		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002016320	A1	20020207	US 2000-215323PP	20000630
			US 2001-896874	20010629
			US 2000-215323PP	20000630
EP 1299349	A2	20030409	EP 2001-950719	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-215323PP	20000630
			WO 2001-US20852W	20010629
US 2003096864	A1	20030522	US 2001-895871	20010629
			US 2000-215323PP	20000630

FAN 2002:31397

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002506	A2	20020110	WO 2001-US20930	20010629
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 2000-215323PP	20000630
US 2002016320	A1	20020207	US 2001-896874	20010629
			US 2000-215323PP	20000630

EP 1299352	A2	20030409	EP 2001-952352	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-215323PP	20000630
			WO 2001-US20930W	20010629
BR 2001011980	A	20030506	BR 2001-11980	20010629
			US 2000-215323PP	20000630
			WO 2001-US20930W	20010629
US 2003096864	A1	20030522	US 2001-895871	20010629
			US 2000-215323PP	20000630
FAN 2002:31402				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI WO 2002002512	A2	20020110	WO 2001-US21012	20010629
WO 2002002512	A3	20030821		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 2000-215323PP	20000630
			US 2000-252736PP	20001122
			US 2000-255956PP	20001215
			US 2001-268497PP	20010213
			US 2001-279779PP	20010329
			US 2001-295589PP	20010604
US 2002128255	A1	20020912	US 2001-896139	20010629
			US 2000-215323PP	20000630
			US 2000-252736PP	20001122
			US 2000-255956PP	20001215
			US 2001-268497PP	20010213
			US 2001-279779PP	20010329
			US 2001-295589PP	20010604
BR 2001012000	A	20030603	BR 2001-12000	20010629
			US 2000-215323PP	20000630
			US 2000-252736PP	20001122
			US 2000-255956PP	20001215
			US 2001-268497PP	20010213
			US 2001-279779PP	20010329
			US 2001-295589PP	20010604
			WO 2001-US21012W	20010629
NO 2002006199	A	20030221	NO 2002-6199	20021223
			US 2000-215323PP	20000630
			US 2000-252736PP	20001122
			US 2000-255956PP	20001215
			US 2001-268497PP	20010213
			US 2001-279779PP	20010329
			US 2001-295589PP	20010604
			WO 2001-US21012W	20010629
FAN 2002:31408				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI WO 2002002518	A2	20020110	WO 2001-US20856	20010629

WO 2002002518 A3 20020808
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2000-215323PP 20000630
 AU 2001073094 A5 20020114 AU 2001-73094 20010629
 US 2000-215323PP 20000630
 WO 2001-US20856W 20010629
 US 2002016320 A1 20020207 US 2001-896874 20010629
 US 2000-215323PP 20000630
 US 2003096864 A1 20030522 US 2001-895871 20010629
 US 2000-215323PP 20000630

OS MARPAT 136:102193


IT **388077-64-3P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of disubstituted amines for treating Alzheimer's disease)



RN 388077-64-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-5-methyl-N,N-dipropyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; X = CO, CH₂, (CH₂)₂, CH₂CO; A = absent, Ph, cyclohexyl, etc.; R4 = (un)substituted alkyl, OH, NO₂, etc.; n = 0-3; Z = CO, SO, SO₂, a bond, etc.; R5 = (un)substituted alkyl, (CH₂)₀₋₃cycloalkyl, etc.; R6 = H, alkyl, alkenyl, etc.; or N(R₆)Z-R₅ may cyclize to form (un)substituted 5-8 membered heterocyclic ring or fused rings], .beta.-secretase inhibitors which are useful in treating Alzheimer's disease and other similar diseases, were prepd. E.g., a multi-step synthesis of (2S,3S)-II, was given. The compds. I exhibited IC₅₀ of < 50 .mu.M against .beta.-secretase.

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:31408 CAPLUS

DN 136:102192

TI Preparation of disubstituted amines for treating Alzheimer's disease

IN Beck, James P.; Gailunas, Andrea; Hom, Roy; Jagodzinska, Barbara; John, Varghese; Maillaird, Michel

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 286 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002518	A2	20020110	WO 2001-US20856	20010629
WO 2002002518	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			



BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001073094	A5	20020114	US 2000-215323PP	20000630
			AU 2001-73094	20010629
			US 2000-215323PP	20000630
			WO 2001-US20856W	20010629
US 2002016320	A1	20020207	US 2001-896874	20010629
			US 2000-215323PP	20000630
US 2003096864	A1	20030522	US 2001-895871	20010629
			US 2000-215323PP	20000630

PATENT FAMILY INFORMATION:

FAN 2002:31396

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002505	A2	20020110	WO 2001-US20852	20010629
	WO 2002002505	A3	20020801		
	W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 2000-215323PP	20000630	
	US 2002016320	A1	20020207	US 2001-896874	20010629
			US 2000-215323PP	20000630	
	EP 1299349	A2	20030409	EP 2001-950719	20010629
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
			US 2000-215323PP	20000630	
			WO 2001-US20852W	20010629	
	US 2003096864	A1	20030522	US 2001-895871	20010629
			US 2000-215323PP	20000630	

FAN 2002:31397

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002506	A2	20020110	WO 2001-US20930	20010629
	W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 2000-215323PP	20000630	
	US 2002016320	A1	20020207	US 2001-896874	20010629
			US 2000-215323PP	20000630	
	EP 1299352	A2	20030409	EP 2001-952352	20010629
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
			US 2000-215323PP	20000630	
			WO 2001-US20930W	20010629	
	BR 2001011980	A	20030506	BR 2001-11980	20010629

	US 2003096864	A1	20030522	US 2000-215323PP	20000630
				WO 2001-US20930W	20010629
				US 2001-895871	20010629
				US 2000-215323PP	20000630
FAN	2002:31402				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2002002512	A2	20020110	WO 2001-US21012	20010629
	WO 2002002512	A3	20030821		
	W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000-215323PP	20000630
				US 2000-252736PP	20001122
				US 2000-255956PP	20001215
				US 2001-268497PP	20010213
				US 2001-279779PP	20010329
				US 2001-295589PP	20010604
	US 2002128255	A1	20020912	US 2001-896139	20010629
				US 2000-215323PP	20000630
				US 2000-252736PP	20001122
				US 2000-255956PP	20001215
				US 2001-268497PP	20010213
				US 2001-279779PP	20010329
				US 2001-295589PP	20010604
	BR 2001012000	A	20030603	BR 2001-12000	20010629
				US 2000-215323PP	20000630
				US 2000-252736PP	20001122
				US 2000-255956PP	20001215
				US 2001-268497PP	20010213
				US 2001-279779PP	20010329
				US 2001-295589PP	20010604
				WO 2001-US21012W	20010629
	NO 2002006199	A	20030221	NO 2002-6199	20021223
				US 2000-215323PP	20000630
				US 2000-252736PP	20001122
				US 2000-255956PP	20001215
				US 2001-268497PP	20010213
				US 2001-279779PP	20010329
				US 2001-295589PP	20010604
				WO 2001-US21012W	20010629
FAN	2002:31410				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2002002520	A2	20020110	WO 2001-US21000	20010702
	W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,			

MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 2000-215323PP	20000630
			US 2001-895843 A	20010629
US 2002143177	A1	20021003	US 2001-895843	20010629
			US 2000-215323PP	20000630
AU 2001073132	A5	20020114	AU 2001-73132	20010702
			US 2000-215323PP	20000630
			US 2001-895843 A	20010629
			WO 2001-US21000W	20010702

OS MARPAT 136:102192


IT **388077-64-3P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of disubstituted amines for treating Alzheimer's disease)


RN 388077-64-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



GI



I



II

AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; X = CO, CH2, (CH2)2, CH2CO; A = absent, Ph, cyclohexyl, etc.; R4 = (un)substituted alkyl, OH, NO2, etc.; n = 0-3; Z = CO, SO, SO2, a bond, etc.; R5 = (un)substituted alkyl, (CH2)0-3cycloalkyl, etc.; R6 = H, alkyl, alkenyl, etc.; or N(R6)ZR5 may cyclize to form (un)substituted 5-8 membered heterocyclic ring or fused rings], .beta.-secretase inhibitors which are useful in treating Alzheimer's disease and other similar diseases, were prepd. E.g., a multi-step synthesis of (2S,3S)-II, was given. The compds. I exhibited IC50 of < 50 .mu.M against .beta.-secretase.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
32.97	289.00


FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.95	-1.95

CA SUBSCRIBER PRICE


STN INTERNATIONAL LOGOFF AT 12:37:05 ON 20 SEP 2003



RN 388077-64-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




Speers

RN 388077-67-6 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(3-thiazolidinyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388077-68-7 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[4-(4-fluorophenyl)-1-piperazinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 388077-59-6P 388077-60-9P 388077-61-0P
388077-62-1P 388077-65-4P 388077-66-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of disubstituted amines for treating Alzheimer's disease)


RN 388077-59-6 CAPLUS
CN Octanoic acid, 8-[[[(2S,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]benzoyl]amino]-2-hydroxybutyl]ethylamino]-8-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388077-60-9 CAPLUS
CN Hexanoic acid, 6-[[[[[(2S,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]benzoyl]amino]-2-hydroxybutyl]ethylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-61-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2S)-3-[(butylsulfonyl)ethylamino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388077-62-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2S)-1-[(3,5-difluorophenyl)methyl]-3-[ethyl[(2-methylpropyl)amino]carbonyl]amino]-2-hydroxypropyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-65-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[methyl[2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-66-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[methyl[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 388077-72-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of disubstituted amines for treating Alzheimer's disease)

RN 388077-72-3 CAPLUS

CN Octanoic acid, 8-[[[(2S,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]benzoyl]amino]-2-hydroxybutyl]ethylamino]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

		BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
			US 2000-215323PP	20000630
US 2002016320		A1 20020207	US 2001-896874	20010629
			US 2000-215323PP	20000630
FAN	2002:31397			
	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	WO 2002002506	A2	20020110	WO 2001-US20930 20010629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002016320	A1	20020207	US 2000-215323PP 20000630
				US 2001-896874 20010629
				US 2000-215323PP 20000630
FAN	2002:31402			
	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	WO 2002002512	A2	20020110	WO 2001-US21012 20010629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000-215323PP 20000630
				US 2000-252736PP 20001122
				US 2000-255956PP 20001215
				US 2001-268497PP 20010213
				US 2001-279779PP 20010329
				US 2001-295589PP 20010604
	US 2002128255	A1	20020912	US 2001-896139 20010629
				US 2000-215323PP 20000630
				US 2000-252736PP 20001122
				US 2000-255956PP 20001215
				US 2001-268497PP 20010213
				US 2001-279779PP 20010329
				US 2001-295589PP 20010604
FAN	2002:31410			
	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	WO 2002002520	A2	20020110	WO 2001-US21000 20010702
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000-215323PP 20000630



L26 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2002 ACS

AN 2002:31408 CAPLUS

DN 136:102192

TI Preparation of disubstituted amines for treating Alzheimer's disease

IN Beck, James P.; Gailunas, Andrea; Hom, Roy; Jagodzinska, Barbara; John, Varghese; Maillaird, Michel

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002518	A2	20020110	WO 2001-US20856	20010629
	WO 2002002518	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001073094	A5	20020114	US 2000-215323PP	20000630
				AU 2001-73094	20010629
				US 2000-215323PP	20000630
				WO 2001-US20856W	20010629
	US 2002016320	A1	20020207	US 2001-896874	20010629
				US 2000-215323PP	20000630

PATENT FAMILY INFORMATION:

FAN 2002:31396

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002505	A2	20020110	WO 2001-US20852	20010629
	WO 2002002505	A3	20020801		
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

Applied

AU 2001073132 A5 20020114



US 2001-895843-A 20010629

AU 2001-73132 20010702

US 2000-215323PP 20000630

US 2001-895843 A 20010629

WO 2001-US21000W 20010702

OS MARPAT 136:102192
GI

AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; X = CO, CH2, (CH2)2, CH2CO; A = absent, Ph, cyclohexyl, etc.; R4 = (un)substituted alkyl, OH, NO2, etc.; n = 0-3; Z = CO, SO, SO2, a bond, etc.; R5 = (un)substituted alkyl, (CH2)0-3cycloalkyl, etc.; R6 = H, alkyl, alkenyl, etc.; or N(R6)ZR5 may cyclize to form (un)substituted 5-8 membered heterocyclic ring or fused rings], .beta.-secretase inhibitors which are useful in treating Alzheimer's disease and other similar diseases, were prepd. E.g., a multi-step synthesis of (2S,3S)-II, was given. The compds. I exhibited IC50 of < 50 .mu.M against .beta.-secretase.


IT 388077-63-2P 388077-64-3P 388077-67-6P
388077-68-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of disubstituted amines for treating Alzheimer's disease)

RN 388077-63-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2S)-2-[[2-methylpropyl]amino]carbonyl]-1-piperidinyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-64-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388077-67-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(3-thiazolidinyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-68-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[4-(4-fluorophenyl)-1-piperazinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 388077-59-6P 388077-60-9P 388077-61-0P

388077-62-1P 388077-65-4P 388077-66-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of disubstituted amines for treating Alzheimer's disease)

RN 388077-59-6 CAPLUS

CN Octanoic acid, 8-[[[(2S,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]benzoyl]amino]-2-hydroxybutyl]ethylamino]-8-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-60-9 CAPLUS

CN Hexanoic acid, 6-[[[[[(2S,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]benzoyl]amino]-2-hydroxybutyl]ethylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-61-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2S)-3-[(butylsulfonyl)ethylamino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388077-62-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2S)-1-[(3,5-difluorophenyl)methyl]-3-[ethyl[(2-methylpropyl)amino]carbonyl]amino]-2-hydroxypropyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-65-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[methyl[2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-66-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[methyl[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 388077-72-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of disubstituted amines for treating Alzheimer's disease)

RN 388077-72-3 CAPLUS

CN Octanoic acid, 8-[[[(2S,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]benzoyl]amino]-2-hydroxybutyl]ethylamino]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2002 ACS

AN 2002:31402 CAPLUS

DN 136:102190

TI Preparation of substituted amines to treat Alzheimer's disease

IN Maillaird, Michel; Hom, Court; Gailunas, Andrea; Jagodzinska, Barbara; Fang, Lawrence Y.; John, Varghese; Freskos, John N.; Pulley, Shon R.; Beck, James P.; Tenbrink, Ruth E.

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 651 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002512	A2	20020110	WO 2001-US21012	20010629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FL, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 2000-215323PP	20000630
			US 2000-252736PP	20001122
			US 2000-255956PP	20001215
			US 2001-268497PP	20010213
			US 2001-279779PP	20010329
			US 2001-295589PP	20010604
US 2002128255	A1	20020912	US 2001-896139	20010629
			US 2000-215323PP	20000630
			US 2000-252736PP	20001122
			US 2000-255956PP	20001215
			US 2001-268497PP	20010213
			US 2001-279779PP	20010329
			US 2001-295589PP	20010604

PATENT FAMILY INFORMATION:

FAN 2002:31396

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002505	A2	20020110	WO 2001-US20852	20010629
WO 2002002505	A3	20020801		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,			

CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
 FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
 TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002016320 A1 20020207

US 2000-215323PP 20000630

US 2001-896874 20010629

US 2000-215323PP 20000630

FAN 2002:31397

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

PI WO 2002002506 A2 20020110

WO 2001-US20930 20010629

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
 FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
 TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002016320 A1 20020207

US 2000-215323PP 20000630

US 2001-896874 20010629

US 2000-215323PP 20000630

FAN 2002:31408

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

PI WO 2002002518 A2 20020110

WO 2001-US20856 20010629

WO 2002002518 A3 20020808

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001073094 A5 20020114

US 2000-215323PP 20000630

AU 2001-73094 20010629

US 2000-215323PP 20000630

WO 2001-US20856W 20010629

US 2002016320 A1 20020207

US 2001-896874 20010629

US 2000-215323PP 20000630

FAN 2002:31410

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

PI WO 2002002520 A2 20020110



WO 2001-US21000 20010702

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
 FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
 TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001073132 A5 20020114

US 2000-215323PP 20000630
US 2001-895843 A 20010629
AU 2001-73132 20010702
US 2000-215323PP 20000630
US 2001-895843 A 20010629
WO 2001-US21000W 20010702

OS MARPAT 136:102190
GI



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; R4 = XR; X = CO, SO₂, a bond, etc.; R = Ph, naphthyl, indanyl, etc.; R5 = (un)substituted alkyl, (CH₂)₀₋₃cycloalkyl, etc.], useful in treating Alzheimer's disease and other similar diseases, were prepd. Thus, reacting (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate with 5-methyl-N,N-dipropylisophthalamic acid in the presence of Et₃N, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in DMF afforded (1S,2R)-II. The compds. I exhibit an IC₅₀ of < 50 .mu.M against beta-secretase.


IT **388064-11-7P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of substituted amines for treating Alzheimer's disease)

RN 388064-11-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-amino-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 388062-16-6P 388062-17-7P 388062-18-8P
388062-19-9P 388062-20-2P 388062-21-3P
388062-22-4P 388062-23-5P 388062-24-6P
388062-25-7P 388062-26-8P 388062-27-9P
388062-28-0P 388062-29-1P 388062-30-4P
388062-31-5P 388062-32-6P 388062-33-7P
388062-34-8P 388062-35-9P 388062-36-0P
388062-37-1P 388062-38-2P 388062-39-3P
388062-40-6P 388062-41-7P 388062-42-8P
388062-43-9P 388062-44-0P 388062-45-1P
388062-46-2P 388062-47-3P 388062-48-4P
388062-49-5P 388062-50-8P 388062-51-9P
388062-52-0P 388062-53-1P 388062-54-2P
388062-55-3P 388062-56-4P 388062-57-5P
388062-58-6P 388062-59-7P 388062-60-0P
388062-61-1P 388062-62-2P 388062-63-3P
388062-64-4P 388062-65-5P 388062-66-6P
388062-67-7P 388062-68-8P 388062-69-9P
388062-70-2P 388062-71-3P 388062-72-4P
388062-73-5P 388062-74-6P 388062-75-7P
388062-76-8P 388062-77-9P 388062-78-0P
388062-79-1P 388062-80-4P 388062-81-5P
388062-82-6P 388062-83-7P 388062-84-8P
388062-85-9P 388062-86-0P 388062-87-1P
388062-88-2P 388062-89-3P 388062-90-6P
388062-91-7P 388062-92-8P 388062-93-9P
388062-94-0P 388062-95-1P 388062-96-2P
388062-97-3P 388062-98-4P 388062-99-5P
388063-00-1P 388063-01-2P 388063-02-3P
388063-03-4P 388063-04-5P 388063-05-6P
388063-06-7P 388063-07-8P 388063-08-9P
388063-09-0P 388063-10-3P 388063-11-4P
388063-12-5P 388063-14-7P 388063-15-8P
388063-16-9P 388063-17-0P 388063-18-1P
388063-19-2P 388063-20-5P 388063-21-6P
388063-22-7P 388063-23-8P 388063-24-9P
388063-25-0P 388063-26-1P 388063-27-2P
388063-28-3P 388063-29-4P 388063-30-7P
388063-31-8P 388063-32-9P 388063-33-0P
388063-34-1P 388063-35-2P 388063-36-3P
388063-37-4P 388063-38-5P 388063-39-6P
388063-40-9P 388063-41-0P 388063-42-1P
388063-43-2P 388063-45-4P 388063-46-5P
388063-47-6P 388063-48-7P 388063-49-8P
388063-50-1P 388063-51-2P 388063-52-3P
388063-53-4P 388063-54-5P 388063-55-6P
388063-56-7P 388063-57-8P 388063-58-9P
388063-59-0P 388063-60-3P 388063-61-4P

388063-62-5P 388063-63-6P 388063-64-7P
388063-65-8P 388063-66-9P 388063-68-1P
388063-73-8P 388063-75-0P 388063-76-1P
388063-77-2P 388063-78-3P 388063-85-2P
388063-86-3P 388063-87-4P 388063-88-5P
388063-89-6P 388063-90-9P 388063-91-0P
388063-92-1P 388063-93-2P 388063-94-3P
388063-95-4P 388063-96-5P 388063-97-6P
388063-98-7P 388063-99-8P 388064-00-4P
388064-01-5P 388064-02-6P 388064-03-7P
388064-04-8P 388064-05-9P 388064-06-0P
388064-07-1P 388064-12-8P 388064-13-9P
388064-14-0P 388064-38-8P 388064-39-9P
388064-40-2P 388064-41-3P 388064-42-4P
388064-43-5P 388064-44-6P 388064-45-7P
388064-46-8P 388064-47-9P 388064-48-0P
388064-49-1P 388064-50-4P 388064-51-5P
388064-52-6P 388064-53-7P 388064-54-8P
388064-55-9P 388064-57-1P 388064-58-2P
388064-59-3P 388064-61-7P 388064-62-8P
388064-65-1P 388064-66-2P 388064-67-3P
388064-70-8P 388064-71-9P 388064-72-0P
388064-73-1P 388064-96-8P 388064-97-9P
388064-98-0P 388065-00-7P 388065-01-8P
388065-02-9P 388065-03-0P 388065-08-5P
388065-09-6P 388065-12-1P 388065-13-2P
388065-15-4P 388065-16-5P 388065-17-6P
388065-19-8P 388065-20-1P 388065-21-2P
388065-22-3P 388065-23-4P 388065-24-5P
388065-27-8P 388065-29-0P 388065-30-3P
388065-31-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted amines for treating Alzheimer's disease)

RN 388062-16-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-17-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(2-furanylmethyl)amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-18-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(ethylamino)-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-19-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-20-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(1-methylethyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-21-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(4-methylphenyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-22-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[2-(4-methoxyphenyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-23-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-24-6 CAPLUS

CN Benzeneacetic acid, .alpha.-[[[(3S)-3-[[3-[(dipropylamino)carbonyl]benzoyl]

amino]-2-hydroxy-4-phenylbutyl]amino]-7-ethyl ester-(9CI) -- (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-25-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S)-2-hydroxy-3-[[1-(phenylmethyl)propyl]amino]-2-hydroxymethyl]-2-(4-nitrophenyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-26-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(2-chlorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-27-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(4-chlorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-28-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[2-(2-hydroxyethoxy)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388062-29-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(2,3-dihydro-1H-inden-1-yl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-30-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(2-hydroxypropyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-31-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[tetrahydro-2-furanyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-32-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(2,2-diethoxyethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-33-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(butylamino)-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-34-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-35-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-pyridinylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-36-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[2-aminophenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-37-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[3-(pyridin-3-ylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-38-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[2-(1-pyrrolidinyl)ethyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-39-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(2-hydroxy-2-phenylethyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-40-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(3-butoxypropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-41-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(1-methylethoxy)propyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-42-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-43-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(3-phenylpropyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-44-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(2-methoxyethyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-45-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(2-phenoxyethyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-46-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(2-propoxyethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-47-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(3,3-dimethylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-48-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(4-phenylbutyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-49-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-iodophenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 388062-50-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-2-hydroxy-3-[[4-nitrophenyl]methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-51-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-3-[[2-(4-chlorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-52-0 CAPLUS


CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-3-[[2-(4-chlorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-53-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[2-(2-pyridinyl)ethyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-54-2 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[4-pyridinylmethyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-55-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[1-methyl-2-(1-pyrrolidinyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388062-56-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2,3-dimethylphenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-57-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[2-(trifluoromethoxy)phenyl]methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-58-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[2-chloro-6-phenoxyphenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-59-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-60-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2,3-dichlorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-61-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3,5-dichlorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-62-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3,5-difluorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-63-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[4-(trifluoromethoxy)phenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-64-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-65-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[4-methoxyphenyl]methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-66-6 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[4-methylphenyl]methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-67-7 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[(3,4,5-trimethoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-68-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[(3-(trifluoromethoxy)phenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-69-9 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[(3,5-dimethoxyphenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388062-70-2 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[(2,4-dimethoxyphenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-71-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[1,1'-biphenyl]-3-ylmethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-72-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3,4-dichlorophenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-73-5 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[2-fluorophenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-74-6 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-75-7 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[2-methylphenyl]methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-76-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[1R)-1-phenylethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388062-77-9 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[1S)-1-phenylethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-78-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-79-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[[2-(trifluoromethyl)phenyl]methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-80-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[1-(1-naphthalenyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-81-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[1R]-1-(1-naphthalenyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-82-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[4-hydroxy-3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-83-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3,4-dihydroxyphenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-84-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxypropyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-85-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(1S)-2-hydroxy-1-methylethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-86-0 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(1R)-2-hydroxy-1-methylethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-87-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(2-propynylamino)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-88-2 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(2-fluorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388062-89-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(3-fluorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388062-90-6 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(4-fluorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-91-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(4-bromophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-92-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S)-2-hydroxy-3-[[2-(3-methoxyphenyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-93-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-94-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(3-chlorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-95-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S)-3-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-96-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[2-(4-methylphenyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-97-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[2-(1-(hydroxymethyl)-2-phenylethyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-98-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(4-morpholinyl)propyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388062-99-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-00-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[2-(4-morpholinyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-01-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(2-hydroxybutyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-02-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[2-(2-thienyl)ethyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-03-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(4-hydroxybutyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-04-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[1-(2-hydroxy-1-phenylethyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-05-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2,4-dichlorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-

dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-06-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(1R)-2-hydroxy-1-phenylethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-07-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-08-9 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(1-phenylethyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-09-0 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 388063-10-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[(3,4-dimethylphenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-11-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388063-12-5 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-14-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[1,1-dimethyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-15-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-16-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1,1-dimethyl-2-[(2-methylpropyl)amino]carbonyl]propyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-17-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(1R)-1-[[(2-methylpropyl)amino]carbonyl]propyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-18-1 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-19-2 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-(ethylamino)-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-20-5 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-[(2-methylpropyl)amino]propyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388063-21-6 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[2-methyl-3-[(2-methylpropyl)amino]-3-oxopropyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-22-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[4-(dimethylamino)phenyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-23-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1S)-2-[(2-methylpropyl)amino]-2-oxo-1-(phenylmethyl)ethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-24-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1S)-2-methyl-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-25-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[2-(dimethylamino)ethyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg; d stat que 18; fil capl; d que nos 19; fil uspatf; d que nos 110
FILE 'REGISTRY' ENTERED AT 15:17:22 ON 26 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2002 HIGHEST RN 455250-99-4
DICTIONARY FILE UPDATES: 25 SEP 2002 HIGHEST RN 455250-99-4


TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L1 STR



*full file search
done on this
structure*

NODE ATTRIBUTES:

NSPEC	IS	RC	AT	1
NSPEC	IS	RC	AT	4
NSPEC	IS	RC	AT	5
NSPEC	IS	RC	AT	6

these nodes are ring or chain

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L2 SCR 1834

L3 11310 SEA FILE=REGISTRY SSS FUL L1 AND L2

L4 STR



*subst search
done on this structure
(species)*

NODE ATTRIBUTES:

NSPEC IS RC AT 15
CONNECT IS E1 RC AT 9
CONNECT IS E1 RC AT 17
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L8 593 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

100.0% PROCESSED 719 ITERATIONS
SEARCH TIME: 00.00.03

593 ANSWERS

FILE 'CAPLUS' ENTERED AT 15:17:23 ON 26 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2002 VOL 137 ISS 13
FILE LAST UPDATED: 25 Sep 2002 (20020925/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L1 STR
L2 SCR 1834
L3 11310 SEA FILE=REGISTRY SSS FUL L1 AND L2
L4 STR
L8 593 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L9 6 SEA FILE=CAPLUS ABB=ON L8

FILE 'USPATFULL' ENTERED AT 15:17:23 ON 26 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 26 Sep 2002 (20020926/PD)
FILE LAST UPDATED: 26 Sep 2002 (20020926/ED)
HIGHEST GRANTED PATENT NUMBER: US6457178

HIGHEST APPLICATION PUBLICATION NUMBER: US2002138890
CA INDEXING IS CURRENT THROUGH 26 Sep 2002 (20020926/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 26 Sep 2002 (20020926/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L1 STR
L2 SCR 1834
L3 11310 SEA FILE=REGISTRY SSS FUL L1 AND L2
L4 STR
L8 593 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L10 14 SEA FILE=USPATFULL ABB=ON L8

=> dup rem 19,110

FILE 'CAPLUS' ENTERED AT 15:17:27 ON 26 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:17:27 ON 26 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L9
PROCESSING COMPLETED FOR L10
L26 20 DUP REM L9 L10 (0 DUPLICATES REMOVED)
ANSWERS '1-6' FROM FILE CAPLUS
ANSWERS '7-20' FROM FILE USPATFULL

=> d fbib abs hitstr 1-6; d ibib abs hitstr 7-20

L26 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2002 ACS
AN 2002:31410 CAPLUS
DN 136:102193
TI Preparation of disubstituted amines for treating Alzheimer's disease
IN Beck, James P.; Gailunas, Andrea; Hom, Roy; Jagodzinska, Barbara; John,
Varghese; Maillaird, Michel
PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SO PCT Int. Appl., 286 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002520	A2	20020110	WO 2001-US21000	20010702
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000-215323PP	20000630
				US 2001-895843 A	20010629
	AU 2001073132	A5	20020114	AU 2001-73132	20010702
				US 2000-215323PP	20000630
				US 2001-895843 A	20010629
				WO 2001-US21000W	20010702

PATENT FAMILY INFORMATION:

FAN 2002:31396

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002505	A2	20020110	WO 2001-US20852	20010629
	WO 2002002505	A3	20020801		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000-215323PP	20000630
	US 2002016320	A1	20020207	US 2001-896874	20010629
				US 2000-215323PP	20000630

FAN 2002:31397

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002506	A2	20020110	WO 2001-US20930	20010629
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000-215323PP	20000630
	US 2002016320	A1	20020207	US 2001-896874	20010629
				US 2000-215323PP	20000630

FAN 2002:31402

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002512	A2	20020110	WO 2001-US21012	20010629
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,			

CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
 FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
 TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002128255 A1 20020912
 US 2000-215323PP 20000630
 US 2000-252736PP 20001122
 US 2000-255956PP 20001215
 US 2001-268497PP 20010213
 US 2001-279779PP 20010329
 US 2001-295589PP 20010604
 US 2001-896139 20010629
 US 2000-215323PP 20000630
 US 2000-252736PP 20001122
 US 2000-255956PP 20001215
 US 2001-268497PP 20010213
 US 2001-279779PP 20010329
 US 2001-295589PP 20010604

FAN 2002:31408

PATENT NO.

KIND

DATE

APPLICATION NO.



DATE

PI WO 2002002518 A2 20020110 WO 2001-US20856 20010629
 WO 2002002518 A3 20020808

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001073094 A5 20020114 AU 2001-73094 20010629
 US 2002016320 A1 20020207 US 2000-215323PP 20000630
 US 2001-896874 20010629
 US 2000-215323PP 20000630

OS MARPAT 136:102193
 GI



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; X = CO, CH2, (CH2)2, CH2CO; A = absent, Ph, cyclohexyl, etc.; R4 = (un)substituted alkyl, OH, NO2, etc.; n = 0-3; Z = CO, SO, SO2, a bond, etc.; R5 = (un)substituted alkyl, (CH2)0-3cycloalkyl, etc.; R6 = H, alkyl, alkenyl, etc.; or N(R6)ZR5 may cyclize to form (un)substituted 5-8 membered heterocyclic ring or fused rings], .beta.-secretase inhibitors which are useful in treating Alzheimer's disease and other similar diseases, were prepd. E.g., a multi-step synthesis of (2S,3S)-II, was given. The compds. I exhibited IC50 of < 50 .mu.M against .beta.-secretase.

IT 388077-63-2P 388077-64-3P 388077-67-6P
388077-68-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of disubstituted amines for treating Alzheimer's disease)

RN 388077-63-2 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2S)-2-[[[(2-methylpropyl)amino]carbonyl]-1-piperidinyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 388063-26-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-pyridinylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-27-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1S)-2-[(2-methylpropyl)amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-28-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1-methyl-1-phenylethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-29-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1R)-2-methyl-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-30-7 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]butyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-31-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(1S)-1-(hydroxymethyl)-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-32-9 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2-phenylethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388063-33-0 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(1S)-1-methyl-2-oxo-2-[(phenylmethyl)amino]ethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-34-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(1S)-1-phenylpropyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-35-2 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(1S)-2-(ethylamino)-1-methyl-2-oxoethyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-36-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1S)-2-[(2-methylpropyl)amino]-2-oxo-1-phenylethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-37-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-methylbutyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388063-38-5 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(cyclohexylamino)-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-39-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(butylamino)-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-40-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-methoxypropyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-41-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-

hydroxy-3-[(2-hydroxy-2-phenylethyl)amino]propyl]-5-methyl-N,N-dipropyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-42-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1R)-1-phenylpropyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-43-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-chlorophenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-45-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[1,1'-biphenyl]-3-ylmethyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-46-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-iodophenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-47-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-methylphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-48-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2-phenylpropyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-49-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(5-thiazolylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-50-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2-thienylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-51-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-52-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(pyrazinylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-53-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3,5-difluorophenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-54-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(1,3-benzodioxol-5-ylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-55-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3,5-dimethoxyphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-56-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-57-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-58-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-(trifluoromethoxy)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-59-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-(4-(trifluoromethoxy)phenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-60-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(1-methylethoxy)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-61-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-bromophenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-62-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(5-methyl-2-furanyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-63-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-64-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-5-methoxy-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-65-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-66-9 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-chloro-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-68-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-5-fluoro-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-73-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methylphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-75-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1R)-2-[(2-methylpropyl)amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388063-76-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1R)-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-77-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-(pentylamino)-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-78-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S)-3-[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-85-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-86-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1R)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-87-4 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-88-5 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2,3-difluorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-89-6 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-fluoro-4-(trifluoromethyl)phenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-90-9 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2,5-difluorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388063-91-0 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-fluoro-5-(trifluoromethyl)phenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-92-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3,4-difluorophenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-93-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-94-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[2-chloro-5-(trifluoromethyl)phenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-95-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-96-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(2,3-dihydro-1H-inden-2-yl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388063-97-6 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S)-2-hydroxy-3-[[[3-nitrophenyl]methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-98-7 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-(difluoromethoxy)phenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388063-99-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-ethoxyphenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388064-00-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[5-methylpyrazinyl]methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388064-01-5 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-bromo-4-fluorophenyl]methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-02-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3,5-dimethylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-03-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-ethoxyphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388064-04-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-[(3,5-difluorophenyl)methyl]-3-[(3-ethoxyphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

hydroxy-3-[(2-phenoxyethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-05-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(2-methylpropoxy)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-06-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[4-methyl-2-thiazolyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-07-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-N-methyl-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-12-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(1,2-diphenylethyl)amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-13-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(1R)-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-14-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(1S)-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-38-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3,5-dimethyl-4-isoxazolyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-39-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-phenylpropyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-40-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3-furanylmethyl)amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-41-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[tetrahydro-3-furanyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-42-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-propoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-43-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2-pyridinyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-44-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-5-hydroxy-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-45-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1-methyl-1-(3-methylphenyl)ethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-46-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-47-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(2,5-dimethylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-48-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[2-chloro-5-(trifluoromethyl)phenyl]methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-49-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[2-hydroxy-5-methylphenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-50-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-51-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-52-6 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-chloro-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1-methyl-1-phenylethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-53-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(2-benzofuranylmethyl)amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-54-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[(1R)-1-(3-bromophenyl)ethyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-55-9 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(4-fluorophenyl)methyl]-2-hydroxy-3-[[[(3-iodophenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388064-57-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-4-methyl-N3,N3-dipropyl- (9CI) (CA INDEX NAME)



RN 388064-58-2 CAPLUS


CN 1,3-Benzenedicarboxamide, N3-[2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-4-methyl-N1,N1-dipropyl- (9CI) (CA INDEX NAME)



RN 388064-59-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-4-methyl-N3,N3-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-61-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-(phenylamino)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-62-8 CAPLUS


CN 1,3-Benzenedicarboxamide, 5-bromo-N'-[(1S,2R)-3-[[3-bromophenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388064-65-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-(3-hydroxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388064-66-2 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-cyano-N'-[(1S,2R)-2-hydroxy-3-[[3-(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 388064-67-3 CAPLUS
CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-70-8 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-(aminosulfonyl)-N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388064-71-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-72-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-[(methyamino)sulfonyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-73-1 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-[(dimethylamino)sulfonyl]-N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-96-8 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-ethyl-N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-97-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-(2-methylpropyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388064-98-0 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-(1,1-dimethylethyl)-N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-00-7 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-01-8 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dimethyl-N',N'-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-02-9 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-3-amino-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-03-0 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-08-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(3,4-dimethylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-09-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-(3-aminophenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388065-12-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1-methyl-1-[3-(trifluoromethyl)phenyl]ethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-13-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-15-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-(1H-isoindol-3-ylamino)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-16-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-17-6 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-chloro-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1-methyl-1-phenylethyl)amino]propyl]-N,N-di-2-propenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-19-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-20-1 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-(dimethylamino)phenyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388065-21-2 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-
[[(4,5-dimethyl-2-furanyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-
dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388065-22-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-
hydroxy-3-[(1-phenylcyclopentyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 388065-23-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(cyclopropylamino)-1-[(3,5-
difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 388065-24-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(cyclopropylmethyl)amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-27-8 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[tetrahydro-2-furanyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388065-29-0 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[(hexahydro-2-oxo-1H-azepin-3-yl)amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388065-30-3 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-methyl-2-furanyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-31-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 388065-32-5P 388065-33-6P 388065-34-7P
388065-35-8P 388065-37-0P 388065-38-1P
388065-39-2P 388065-42-7P 388065-43-8P
388065-45-0P 388065-47-2P 388065-48-3P
388065-49-4P 388065-50-7P 388065-51-8P
388065-52-9P 388065-53-0P 388065-54-1P
388065-55-2P 388065-57-4P 388065-58-5P
388065-59-6P 388065-60-9P 388065-62-1P
388065-63-2P 388065-64-3P 388065-65-4P
388065-66-5P 388065-67-6P 388065-69-8P
388065-70-1P 388065-71-2P 388065-72-3P
388065-73-4P 388065-76-7P 388065-77-8P
388065-78-9P 388065-79-0P 388065-80-3P
388065-81-4P 388065-82-5P 388065-83-6P
388065-84-7P 388065-85-8P 388065-86-9P
388065-87-0P 388065-88-1P 388065-89-2P
388065-90-5P 388065-91-6P 388065-92-7P
388065-93-8P 388065-94-9P 388065-95-0P
388065-96-1P 388065-97-2P 388065-98-3P

388065-99-4P 388066-00-0P 388066-01-1P
388066-02-2P 388066-03-3P 388066-04-4P
388066-05-5P 388066-06-6P 388066-07-7P
388066-08-8P 388066-12-4P 388066-14-6P
388066-16-8P 388066-17-9P 388066-18-0P
388066-19-1P 388066-20-4P 388066-21-5P
388066-22-6P 388066-23-7P 388066-24-8P
388066-25-9P 388066-26-0P 388066-27-1P
388066-31-7P 388066-32-8P 388066-33-9P
388066-34-0P 388066-38-4P 388066-39-5P
388066-49-7P 388066-50-0P 388066-51-1P
388066-52-2P 388066-53-3P 388066-54-4P
388066-55-5P 388066-56-6P 388066-57-7P
388066-58-8P 388066-59-9P 388066-60-2P
388066-61-3P 388066-70-4P 388066-71-5P
388066-72-6P 388066-73-7P 388066-81-7P
388066-82-8P 388066-86-2P 388066-88-4P
388066-91-9P 388066-96-4P 388066-98-6P
388067-02-5P 388067-03-6P 388067-04-7P
388067-05-8P 388067-06-9P 388067-07-0P
388067-08-1P 388067-09-2P 388067-13-8P
388067-14-9P 388067-18-3P 388067-21-8P
388067-23-0P 388067-28-5P 388067-29-6P
388067-42-3P 388067-43-4P 388067-44-5P
388067-45-6P 388067-46-7P 388067-47-8P
388067-48-9P 388067-49-0P 388067-51-4P
388067-52-5P 388067-53-6P 388067-54-7P
388067-55-8P 388067-56-9P 388067-57-0P
388067-59-2P 388067-61-6P 388067-62-7P
388067-63-8P 388067-64-9P 388067-66-1P
388067-67-2P 388067-71-8P 388067-72-9P
388067-73-0P 388067-75-2P 388067-76-3P
388067-78-5P 388067-79-6P 388067-80-9P
388067-81-0P 388067-82-1P 388067-83-2P
388067-84-3P 388067-85-4P 388067-86-5P
388067-87-6P 388067-89-8P 388067-90-1P
388067-91-2P 388067-92-3P 388067-93-4P
388067-94-5P 388067-95-6P 388067-96-7P
388067-97-8P 388067-98-9P 388067-99-0P
388068-00-6P 388068-37-9P 388068-38-0P
388068-39-1P 388068-40-4P 388068-41-5P
388068-42-6P 388068-43-7P 388068-51-7P
388068-52-8P 388068-53-9P 388068-54-0P
388068-55-1P 388068-56-2P 388068-57-3P
388068-58-4P 388068-59-5P 388068-60-8P
388068-61-9P 388068-62-0P 388068-63-1P
388068-64-2P 388068-65-3P 388068-66-4P
388068-67-5P 388068-68-6P 388068-69-7P
388068-70-0P 388068-71-1P 388068-72-2P
388068-73-3P 388068-74-4P 388068-75-5P
388068-76-6P 388068-77-7P 388068-78-8P
388068-79-9P 388068-80-2P 388068-81-3P
388068-82-4P 388068-83-5P 388068-84-6P
388068-85-7P 388068-86-8P 388068-87-9P
388068-88-0P 388068-89-1P 388068-90-4P
388068-91-5P 388068-92-6P 388068-93-7P
388068-94-8P 388068-96-0P 388068-98-2P
388068-99-3P 388069-00-9P 388069-01-0P
388069-02-1P 388069-03-2P 388069-04-3P
388069-05-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of substituted amines for treating Alzheimer's disease).

RN 388065-32-5 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-chloro-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1-methyl-1-phenylethyl)amino]propyl]-N,N-di-2-propynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-33-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-(1-methylethenyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-34-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2-propoxyethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-35-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-(hexylamino)-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-37-0 CAPLUS

CN Benzoic acid, 4-[[[(2R,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]-2-hydroxybutyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388065-38-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2-methoxyethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 388065-39-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(5-isoxazolylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388065-42-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[2-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388065-43-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(1-methylethyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-45-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(3-amino-3-oxopropyl)amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-47-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-(3-iodophenyl)methyl]amino]propyl]-5-ethynyl-N,N-dipropyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-48-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-(3-ethynylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-49-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[2-methyl-5-thiazolyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-50-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[2-ethyl-5-thiazolyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-51-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3R)-hexahydro-2-oxo-1H-azepin-3-yl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-52-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-3-(cyclobutylamino)-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-53-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(butylamino)-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-ethynyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-54-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-ethynyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-55-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-(5-hexynylamino)-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-57-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1-methyl-1-phenylethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-58-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[1-(2-furanyl)-1-methylethyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-59-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(2-methylpropyl)-5-isoxazolyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-60-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[2-(2-methylpropyl)-5-thiazolyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-62-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(2-phenylethyl)amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-63-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-(2-chlorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-64-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-65-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(cyclohexylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-66-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(cyclopropylamino)-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-67-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(hexahydro-2-oxo-1H-azepin-3-yl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-69-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-[(2-ethylhexyl)oxy]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-70-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[1S,2R]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-71-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[1-(4-hydroxyphenyl)ethyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-72-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-(cycloheptylamino)-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-73-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[1,1'-biphenyl]-2-ylmethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388065-76-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

$$-N(\text{Pr}-n)_2$$

RN 388065-77-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[2-[[[2-chloro-6-fluorophenyl)methyl]thio]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-78-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-79-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-(1-naphthalenylamino)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-80-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1H-imidazol-4-ylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-81-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2-phenyl-1H-imidazol-4-yl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-82-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1-methyl-1H-imidazol-2-yl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-83-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[(2-butyl-5-chloro-1H-imidazol-4-yl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-84-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[6-chloroimidazo[2,1-b]thiazol-5-yl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-85-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[1-methyl-1H-benzimidazol-2-yl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-86-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[2-hydroxy-1-naphthalenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-87-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[4-oxo-4H-1-benzopyran-3-yl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-88-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-89-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[5-cyano-6-(methylthio)-2-pyridinyl]methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-90-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[5-[(acetyloxy)methyl]-2-furanyl]methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-91-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(3-benzofuranylmethyl)amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-92-7 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-[[[(2R,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]-2-hydroxybutyl]amino]methyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-93-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[1-(phenylsulfonyl)-1H-pyrrol-2-yl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-94-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-95-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-96-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-97-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-3-[[[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-98-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-phenyl-1H-pyrazol-4-yl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388065-99-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[5-chloro-2-thienyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-00-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(3-phenoxy-2-thienyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-01-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(3-quinolinylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-02-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(2-quinolinylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388066-03-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1-methyl-1H-indol-2-yl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-04-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[1-(phenylmethyl)-1H-indol-3-yl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-05-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[1-methyl-1H-indol-3-yl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-06-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-07-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[2-butyl-1H-imidazol-4-yl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-08-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[[[(2R,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]-2-hydroxybutyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-12-4 CAPLUS


CN 1,3-Benzenedicarboxamide, 5-(cyanomethyl)-N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-14-6 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-(hydroxymethyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-16-8 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-ethynyl-N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-17-9 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-iodophenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-(1-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388066-18-0 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-ethynyl-N'-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[[3-(trifluoromethyl)phenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-19-1 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-ethynyl-N'-[(1S,2R)-2-hydroxy-3-[[3-iodophenyl]methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-20-4 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-ethynyl-N'-[(1S,2R)-2-hydroxy-3-[[3-(fluorophenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-21-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-(8-quinolinyl)-N,N-dipropyl- (8-quinolinyl) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-22-6 CAPLUS

CN [1,1'-Biphenyl]-3,5-dicarboxamide, N'--[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-4'-methoxy-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-23-7 CAPLUS

CN [1,1'-Biphenyl]-3,5-dicarboxamide, N'--[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-24-8 CAPLUS

CN [1,1'-Biphenyl]-3,5-dicarboxamide, N'--[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388066-25-9 CAPLUS

CN [1,1'-Biphenyl]-3,5-dicarboxamide, 4'--[(dimethylamino)sulfonyl]-N'--[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-26-0 CAPLUS


CN [1,1'-Biphenyl]-3,5-dicarboxamide, 4'--[(dimethylamino)sulfonyl]-N'--[(1S,2R)-2-hydroxy-3-[[(3-iodophenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-27-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-(3-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-31-7 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[[3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388066-32-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-(2,4-dimethylphenyl)propyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-33-9 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(4-

methylphenyl)propyl]amino]-1-(phenylmethyl)propyl]-5-methyl-N,N-dipropyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-34-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-methyl-N,N-dipropyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-38-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-4-methyl-N3,N3-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-39-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N3-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-4-methyl-N1,N1-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-49-7 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N,N',N'-tetrapropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-50-0 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-51-1 CAPLUS

CN Benzoic acid, 3-[(dipropylamino)carbonyl]-5-[[[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-52-2 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-53-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-[[(trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-54-4 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-amino-N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 388066-55-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-56-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-[(methanesulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-57-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-[(2-

thienylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-58-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-[(2-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-59-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-[(2-methyl-1-oxo-2-propenyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-60-2 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-[(2,2-dimethyl-1-oxopropyl)amino]-N'-[(1S,2R)-

2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-61-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-[(phenylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-70-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-71-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl-5-[[[(trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-72-6 CAPLUS

CN Benzoic acid, 3-[(dipropylamino)carbonyl]-5-[[[(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-73-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl-5-(2-propynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-81-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-5-(3,5-dimethyl-4-isoxazolyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-82-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl-5-(2-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-86-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-(4-methoxyphenyl)methyl]amino]-2-hydroxypropyl]-5-(4-methyl-2-oxazolyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-88-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(2-methylpropyl)-1,2,4-oxadiazol-5-yl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388066-91-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(4-hydroxy-1-butynyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


OH

RN 388066-96-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-ethylphenyl]methyl]amino]-2-hydroxypropyl]-N-ethyl-N,5-dimethyl-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388066-98-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-
[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,5-dimethyl-N-2-propynyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-02-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-
[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-diethyl-5-methyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-03-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-04-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-05-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N-butyl-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-06-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,5-dimethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-07-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-08-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N-ethyl-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-09-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-
[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-di-2-propenyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-13-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-
[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-bis(1-
methylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-14-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N-butyl-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-18-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[1-(3-methylphenyl)cyclopropyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-21-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-23-0 CAPLUS

CN [1,1'-Biphenyl]-3,5-dicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-4'-methoxy-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 388067-28-5 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-bromo-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-iodophenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-29-6 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(1-phenylcyclopropyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-42-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(3-pyridinyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388067-43-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(4-pyridinyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-44-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl-5-(1-propynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-45-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl-5-(1-propynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-46-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl-5-(2-propynyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-47-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-48-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(phenylmethyl)amino]-1-(3-thienylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-49-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(2-thienylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-51-4 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(3-thienylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-52-5 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(phenylmethyl)amino]-1-(2-thienylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-53-6 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-(3-furanylmethyl)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388067-54-7 CAPLUS
 CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-1-[[4-(phenylmethoxy)phenyl)methyl]-3-[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-55-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-(2-furanylmethyl)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-56-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-[(phenylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-57-0 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-1-(1-naphthalenylmethyl)-3-[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-59-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-(3-furanylmethyl)-2-hydroxy-3-[(phenylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-61-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(4-fluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-62-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(4-fluorophenyl)methyl]-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-63-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-(2-furanylmethyl)-2-hydroxy-3-[(phenylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-64-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(1-naphthalenylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-66-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-67-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-3-[(phenylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-71-8 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-[[4-(phenylmethoxy)phenyl)methyl]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-72-9 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(4-

hydroxyphenyl)methyl]-3-[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388067-73-0 CAPLUS

1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(1-naphthalenylmethyl)propyl]-N,N-dipropyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-75-2 CAPLUS


1,3,5-Benzenetricarboxamide, N'-[1*S*,2*R*]-1-[(4-fluorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-76-3 CAPLUS
CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-(3-furanylmethyl)-2-hydroxy-3-
[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-78-5 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(4-fluorophenyl)methyl]-2-hydroxy-3-
[(phenylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 388067-79-6 CAPLUS
CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-(2-furanylmethyl)-2-hydroxy-3-
[(phenylmethyl)amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-80-9 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(1-naphthalenylmethyl)-3-[(phenylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-81-0 CAPLUS
CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-(cyclohexylmethyl)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388067-82-1 CAPLUS
CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(phenylmethyl)amino]-1-(2-thienylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-83-2 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-(3-furanylmethyl)-2-hydroxy-3-
[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 388067-84-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[[4-(
phenylmethoxy)phenyl]methyl]-3-[(phenylmethyl)amino]propyl]-5-methyl-N,N-
dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-85-4 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-(2-furanylmethyl)-2-hydroxy-3-
[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 388067-86-5 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(phenylmethyl)amino]-1-(3-thienylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-87-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(2-thienylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-89-8 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-

methoxyphenyl)methyl]amino]-1-(3-thienylmethyl)propyl]-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388067-90-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[[3-(hydroxymethyl)phenyl]methyl]-3-[[3-(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-91-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-(ethylphenyl)methyl]amino]-2-hydroxy-1-[[3-(hydroxymethyl)phenyl]methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-92-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[[3-(hydroxymethyl)phenyl]methyl]-3-[[3-(3-iodophenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-93-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[[4-(hydroxymethyl)phenyl]methyl]-3-[[3-(3-iodophenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388067-94-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-(3-ethylphenyl)methyl]amino]-2-hydroxy-1-[[4-(hydroxymethyl)phenyl]methyl]propyl]-5-methyl-N,N-dipropyl-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-95-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[[4-(hydroxymethyl)phenyl]methyl]-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-96-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3-fluoro-5-hydroxyphenyl)methyl]-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-97-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-ethylphenyl)methyl]amino]-1-[(3-fluoro-5-hydroxyphenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-98-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3-fluoro-5-hydroxyphenyl)methyl]-2-hydroxy-3-[[[3-iodophenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388067-99-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[[3-fluoro-5-(phenylmethoxy)phenyl]methyl]-2-hydroxy-3-[[3-iodophenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-00-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[[3-fluoro-5-(phenylmethoxy)phenyl]methyl]-2-hydroxy-3-[[3-methoxyphenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-37-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl-5-[(trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-38-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(3-ethylphenyl)methyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-N,N-dipropyl-5-[(trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-39-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-methyl[(trifluoromethyl)sulfonyl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-40-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-5-methyl[(trifluoromethyl)sulfonyl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-41-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl-5-[propyl[(trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-42-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-5-[(methylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-43-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-5-[(phenylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-51-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[(3-cyclopropylphenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-52-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(2-thiazolyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-53-9 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(2-oxazolyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388068-54-0 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-(4-isoxazol-5-ylphenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 388068-55-1 CAPLUS
 CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-3-[[[3-(4-acetylphenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-N,N-dipropyl- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 388068-56-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-(3-acetylphenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-(aminosulfonyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-57-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-(3-acetylphenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-(methylsulfonyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-58-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-(diethylamino)phenyl]methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-59-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(4-morpholinyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-60-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(1-piperazinyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-61-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-(aminosulfonyl)phenyl]methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-62-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-[(dimethylamino)sulfonyl]phenyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-63-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(1-piperidinylsulfonyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-64-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(methylsulfonyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-65-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-[(1-methylethyl)sulfonyl]phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-66-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[[3-(aminocarbonyl)phenyl]methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-67-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-[(dimethylamino)carbonyl]phenyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-68-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-(3-cyanophenyl)methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388068-69-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-[(aminocarbonyl)oxy]phenyl]methyl]amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-70-0 CAPLUS

CN Carbamic acid, dimethyl-, 3-[[[(2R,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]-2-hydroxybutyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-71-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(1-propynyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-72-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(3-methyl-1-butynyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-73-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(2-propynyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-74-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[2-ethyl-5-oxazolyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-75-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[2-(2-methylpropyl)-5-oxazolyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-76-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[5-(2-methylpropyl)-1,3,4-oxadiazol-2-yl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-77-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-78-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[5-ethyl-1,3,4-thiadiazol-2-yl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-79-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[5-ethyl-1,3,4-oxadiazol-2-yl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-80-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethyl-1,2,4-oxadiazol-5-yl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-81-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethyl-1,2,4-thiadiazol-5-yl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-82-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-(2-methylpropyl)-1,2,4-thiadiazol-5-yl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-83-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[2-ethyl-2H-tetrazol-5-yl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-84-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[2-(2-methylpropyl)-2H-tetrazol-5-yl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-85-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[2-ethyl-4-pyrimidinyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-86-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[2-(1-methylethyl)-4-pyrimidinyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-87-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[2-(1-methylethyl)-4-pyrimidinyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-88-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[6-(1-methylethyl)-4-pyrimidinyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-89-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[6-(dimethylamino)-4-pyrimidinyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-90-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[2-(dimethylamino)-4-pyrimidinyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-91-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[4-(dimethylamino)-2-pyrimidinyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-92-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[4-(1-methylethyl)-2-pyrimidinyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-93-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[4-ethyl-2-pyrimidinyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-94-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[5-ethyl-3-pyridazinyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-96-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[5-(1-methylethyl)-3-pyridazinyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-98-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[6-(1-methylethyl)-4-pyridazinyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388068-99-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[6-ethyl-4-pyridazinyl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-00-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[6-ethylpyrazinyl)methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-01-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[6-(1-methylethyl)pyrazinyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-02-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-[(3,4,5-trifluorophenyl)methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-03-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(trifluoromethyl)phenyl)methyl]amino]-1-[(3,4,5-trifluorophenyl)methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-04-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(2,3,5,6-tetrafluorophenyl)methyl]-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-05-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[3-methoxyphenyl]methyl]amino]-1-[(2,3,5,6-tetrafluorophenyl)methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 388069-06-5P 388069-07-6P 388069-08-7P
 388069-09-8P 388069-10-1P 388069-11-2P
 388069-12-3P 388069-13-4P 388069-14-5P
 388069-15-6P 388069-16-7P 388069-17-8P
 388069-18-9P 388069-19-0P 388069-20-3P
 388069-21-4P 388069-22-5P 388069-24-7P
 388069-26-9P 388069-28-1P 388069-29-2P
 388069-31-6P 388069-34-9P 388069-36-1P
 388069-38-3P 388069-40-7P 388069-42-9P
 388069-43-0P 388069-44-1P 388069-45-2P
 388069-46-3P 388069-47-4P 388069-48-5P
 388069-49-6P 388069-50-9P 388069-51-0P
 388069-52-1P 388069-53-2P 388069-54-3P
 388069-55-4P 388069-56-5P 388069-57-6P
 388069-58-7P 388069-59-8P 388069-60-1P
 388069-61-2P 388069-62-3P 388069-63-4P
 388069-64-5P 388069-65-6P 388069-66-7P
 388069-67-8P 388069-69-0P 388069-70-3P
 388069-71-4P 388069-72-5P 388070-41-5P
 388070-45-9P 388070-47-1P 388070-49-3P
 388070-51-7P 388070-54-0P 388070-56-2P
 388070-58-4P 388070-61-9P 388070-62-0P
 388070-63-1P 388070-64-2P 388070-65-3P
 388070-66-4P 388070-67-5P 388070-68-6P
 388070-69-7P 388070-70-0P 388070-71-1P
 388070-72-2P 388070-73-3P 388070-74-4P
 388070-75-5P 388070-97-1P 388070-98-2P
 388070-99-3P 388071-00-9P 388071-79-2P
 388071-81-6P 388071-85-0P 388072-01-3P
 388072-04-6P 388072-05-7P 388072-06-8P
 388072-07-9P 388072-20-6P 388072-21-7P
 388072-22-8P 388569-62-8P 388569-63-9P
 388569-64-0P 388569-65-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of substituted amines for treating Alzheimer's disease)

RN 388069-06-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-
 [[[(1R,2S)-2,3-dihydro-2-hydroxy-6-methoxy-1H-inden-1-yl]methyl]amino]-2-
 hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-07-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-6-methoxy-1H-inden-1-yl]methyl]amino]-2-hydroxypropyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-08-7 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(1R,2S)-6-ethyl-2,3-dihydro-2-hydroxy-1H-inden-1-yl]methyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-09-8 CAPLUS
 CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-
 [[[(1R,2S)-6-ethyl-2,3-dihydro-2-hydroxy-1H-inden-1-yl]methyl]amino]-2-
 hydroxypropyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388069-10-1 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-(1H-indol-5-ylmethyl)-3-
 [[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 388069-11-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[[3-ethylphenyl)methyl]amino]-2-hydroxy-1-(1H-indol-5-ylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-12-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-[(3-methylphenyl)methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-13-4 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-[(3-methylphenyl)methyl]propyl]-N,N-dipropyl-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-14-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-[[3-(trifluoromethyl)phenyl)methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-15-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-[[3-(trifluoromethyl)phenyl)methyl]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-16-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(2-pyridinylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-17-8 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(2-pyridinylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-18-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxy-3-[[3-methoxyphenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-19-0 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxy-3-[[3-methoxyphenyl]methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-20-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl]methyl]amino]-1-[[3-(trifluoromethoxy)phenyl]methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-21-4 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-[[3-(trifluoromethoxy)phenyl)methyl]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-22-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(3-hydroxyphenyl)methyl]-3-[[3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-24-7 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(3-

hydroxyphenyl)methyl]-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-26-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-[(4-methylphenyl)methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-28-1 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-[(4-methylphenyl)methyl]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-29-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(4-fluoro-3-methylphenyl)methyl]-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-31-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(4-fluoro-3-methylphenyl)methyl]-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-34-9 CAPLUS

1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(4-chlorophenyl)methyl]-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388069-36-1 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(4-chlorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-38-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(3-methoxyphenyl)methyl]-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-40-7 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(3-methoxyphenyl)methyl]-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-42-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(4-methoxyphenyl)methyl]-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-43-0 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(4-methoxyphenyl)methyl]-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-44-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3-chloro-5-fluorophenyl)methyl]-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-45-2 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3-chloro-5-fluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-46-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(4-chloro-3-fluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-47-4 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(4-chloro-3-fluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-48-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'--[(1S,2R)-1-[(3,5-dichlorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-49-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'--[(1S,2R)-1-[(3,5-dichlorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-50-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[[4-(dimethylamino)phenyl]methyl]-2-hydroxy-3-[[3-methoxyphenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-51-0 CAPLUS


CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[[4-(dimethylamino)phenyl]methyl]-2-hydroxy-3-[[3-methoxyphenyl]methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-52-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3-chlorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 388069-53-2 CAPLUS
CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3-chlorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388069-54-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3-fluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388069-55-4 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3-fluorophenyl)methyl]-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-56-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-[[4-(1-methylethyl)phenyl)methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-57-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-

methoxyphenyl)methyl]amino]-1-[[4-(1-methylethyl)phenyl]methyl]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-58-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[3-methoxyphenyl]methyl]amino]-1-[[6-methoxy-2-pyridinyl]methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-59-8 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[[3-methoxyphenyl]methyl]amino]-1-[[6-methoxy-2-pyridinyl]methyl]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-60-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-[(5-methyl-2-pyridinyl)methyl]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-61-2 CAPLUS


CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-[(5-methyl-2-pyridinyl)methyl]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-62-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3-fluoro-4-methylphenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-63-4 CAPLUS
CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3-fluoro-4-methylphenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388069-64-5 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3-fluoro-4-methoxyphenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-65-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(3-fluoro-4-methoxyphenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-66-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(2-methoxy-5-methylphenyl)methyl]-3-[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-67-8 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-1-[(2-methoxy-5-methylphenyl)methyl]-3-[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-69-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(2-thiazolylmethyl)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-70-3 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]-1-(2-thiazolylmethyl)propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388069-71-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(5-chloro-2-thienyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388069-72-5 CAPLUS

CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-1-[(5-chloro-2-thienyl)methyl]-2-

hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl--(9CI)--(CA INDEX NAME)


Absolute stereochemistry.



RN 388070-41-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-4-hydroxy-N3-methyl-N3-(2-methylpropyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-45-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-4-hydroxy-N3-methyl-N3-propyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-47-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-4-hydroxy-N3-methyl-N3-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-49-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(3-methoxyphenyl)methyl]amino]propyl]-N3-ethyl-4-hydroxy-N3-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-51-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N3-ethyl-4-hydroxy-N3-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-54-0 CAPLUS


CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-4-hydroxy-N3,N3-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388070-56-2 CAPLUS
CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(3-methoxyphenyl)methyl]amino]propyl]-4-hydroxy-N3,N3-dipropyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388070-58-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N1-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[(3-iodophenyl)methyl]amino]propyl]-4-hydroxy-N3,N3-dipropyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-61-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[(methylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-62-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[(ethylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-63-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl-5-[(propylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-64-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[[(1-methylethyl)sulfonyl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-65-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[[(2-methylpropyl)sulfonyl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-66-4 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl-5-[(2-thienylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388070-67-5 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[(2-furanylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388070-68-6 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl-5-[(5-thiazolylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-69-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[(5-oxazolylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-70-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[(4-oxazolylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-71-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl-5-[(4-thiazolylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-72-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-73-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5-[(phenylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-74-4 CAPLUS

CN 1,3-Benzenedicarboxamide, 5-[[[5-cyano-2-pyridinyl)sulfonyl]amino]-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-75-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[3-(3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-N,N-dipropyl-5-[[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-97-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-methylbutyl)amino]propyl]-N,N-dipropyl-5-[[[5-(trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-98-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-amino-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-N,N-dipropyl-5-[[trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388070-99-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-amino-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-[(methylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388071-00-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-methylbutyl)amino]propyl]-5-[(methylsulfonyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388071-79-2 CAPLUS

CN [1,1'-Biphenyl]-3,5-dicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]propyl]-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 388071-81-6 CAPLUS
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 388071-85-0 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-(3-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 388072-01-3 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(4-methylphenyl)propyl]amino]-1-(phenylmethyl)propyl]-5-methyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 388072-04-6 CAPLUS
 CN 1,3,5-Benzenetricarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-(4-methoxyphenyl)propyl]amino]-1-(phenylmethyl)propyl]-N,N,N',N'-tetrapropyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 388072-05-7 CAPLUS

CN Benzoic acid, 3-[(dipropylamino)carbonyl]-5-[[[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 388072-06-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-5-[(methylsulfonyl)amino]-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 388072-07-9 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-2-hydroxy-3-[[3-methoxyphenyl)methyl]amino]-1-(phenylmethyl)propyl]-N,N-dipropyl-5-[(2-thienylsulfonyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 388072-20-6 CAPLUS
 CN 1,3-Benzenedicarboxamide, 5-bromo-N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-iodophenyl)methyl]amino]propyl]-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 388072-21-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-[(1-acetyl-4-piperidiny)amino]-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 388072-22-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[3-(1-pentynyl)phenyl]methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388569-62-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[(3R,5S)-3,5-dimethoxycyclohexyl]amino]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388569-63-9 CAPLUS

CN 1,3-Cyclohexanedicarboxylic acid, 5-[[(2R,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]-2-hydroxybutyl]amino]-, dimethyl ester, (1R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388569-64-0 CAPLUS

CN 1,3-Cyclohexanedicarboxylic acid, 5-[[[(2R,3S)-4-(3,5-difluorophenyl)-3-[[3-[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]-2-hydroxybutyl]amino]-, (1R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388569-65-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(7-oxabicyclo[2.2.1]hept-2-ylmethyl)amino]propyl]-5-methyl-N,N-dipropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 388086-41-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of substituted amines for treating Alzheimer's disease)

RN 388086-41-7 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(3-iodophenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 388063-46-5

CMF C32 H38 F2 I N3 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 388071-31-6P 388071-33-8P 388071-39-4P
388072-15-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of substituted amines for treating Alzheimer's disease)

RN 388071-31-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-azido-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388071-33-8 CAPLUS


CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-3-amino-1-[(3,5-difluorophenyl)methyl]-2-hydroxypropyl]-5-methyl-N,N-dipropyl-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 388064-11-7


CMF C25 H33 F2 N3 O3

Absolute stereochemistry.




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 388071-39-4 CAPLUS
CN Carbamic acid, [(2R,3S)-3-[[3-cyano-5-[(dipropylamino)carbonyl]benzoyl]amino]-2-hydroxy-4-phenylbutyl][(3-methoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388072-15-9 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[3-[(trimethylsilyl)ethynyl]phenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2002 ACS
AN 2002:31397 CAPLUS
DN 136:96075
TI Compounds to treat Alzheimer's disease
IN Fang, Lawrence Y.; John, Varghese
PA Elan Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 434 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002506	A2	20020110	WO 2001-US20930	20010629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002016320	A1	20020207	US 2000-215323PP	20000630
				US 2001-896874	20010629
				US 2000-215323PP	20000630

PATENT FAMILY INFORMATION:

FAN 2002:31396

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002505	A2	20020110	WO 2001-US20852	20010629
	WO 2002002505	A3	20020801		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002016320	A1	20020207	US 2000-215323PP	20000630
				US 2001-896874	20010629
				US 2000-215323PP	20000630


FAN 2002:31402

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002512	A2	20020110	WO 2001-US21012	20010629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002128255	A1	20020912	US 2000-215323PP	20000630
				US 2000-252736PP	20001122
				US 2000-255956PP	20001215
				US 2001-268497PP	20010213
				US 2001-279779PP	20010329
				US 2001-295589PP	20010604
				US 2001-896139	20010629
				US 2000-215323PP	20000630
				US 2000-252736PP	20001122
				US 2000-255956PP	20001215
				US 2001-268497PP	20010213
				US 2001-279779PP	20010329

FAN 2002:31408 US 2001-295589PP 20010604
PATENT NO. KIND DATE APPLICATION NO. DATE


PI WO 2002002518 A2 20020110 WO 2001-US20856 20010629
WO 2002002518 A3 20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001073094 A5 20020114 US 2000-215323PP 20000630
AU 2001-73094 20010629
US 2000-215323PP 20000630
US 2001-US20856W 20010629
US 2001-896874 20010629
US 2000-215323PP 20000630
FAN 2002:31410
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2002002520 A2 20020110 WO 2001-US21000 20010702
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001073132 A5 20020114 US 2000-215323PP 20000630
US 2001-895843 A 20010629
AU 2001-73132 20010702
US 2000-215323PP 20000630
US 2001-895843 A 20010629
WO 2001-US21000W 20010702
OS MARPAT 136:96075
AB The present invention is substituted amines of formula (XV) useful in
treating Alzheimer's disease and other similar diseases.
IT 388083-43-0 388083-44-1 388083-45-2
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(comps. to treat Alzheimer's disease and other cognitive impairment
disorders in relation to inhibition of .beta.-secretase and cleavage of
amyloid precursor protein and combination with other agents)
RN 388083-43-0 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-
(2-methyl-2-phenylhydrazino)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA
INDEX NAME)




RN 388083-44-1 CAPLUS

CN Pentanoic acid, 4-methyl-, 2-[4-(3,5-difluorophenyl)-3-[[3-
[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]-2-hydroxybutyl]-1-
methylhydrazide (9CI) (CA INDEX NAME)



RN 388083-45-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-
(phenoxyamino)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



L26 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2002 ACS

AN 2002:31396 CAPLUS

DN 136:102189

TI Preparation of substituted amines for treating Alzheimer's disease

IN Fang, Lawrence Y.; Hom, Roy; John, Varghese; Maillaird, Michel

PA Elan Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002505	A2	20020110	WO 2001-US20852	20010629
	WO 2002002505	A3	20020801		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
 FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
 TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002016320 A1 20020207

US 2000-215323PP 20000630

US 2001-896874 20010629

US 2000-215323PP 20000630

PATENT FAMILY INFORMATION:

FAN 2002:31397

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002506	A2	20020110	WO 2001-US20930	20010629
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2000-215323PP 20000630				
US 2002016320	A1	20020207	US 2001-896874	20010629
US 2000-215323PP 20000630				

FAN 2002:31402



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002512	A2	20020110	WO 2001-US21012	20010629
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2000-215323PP 20000630				
US 2000-252736PP 20001122				
US 2000-255956PP 20001215				
US 2001-268497PP 20010213				
US 2001-279779PP 20010329				
US 2001-295589PP 20010604				
US 2002128255	A1	20020912	US 2001-896139	20010629
US 2000-215323PP 20000630				
US 2000-252736PP 20001122				
US 2000-255956PP 20001215				
US 2001-268497PP 20010213				
US 2001-279779PP 20010329				
US 2001-295589PP 20010604				

FAN 2002:31408

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002518	A2	20020110	WO 2001-US20856	20010629
WO 2002002518	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EG, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2000-215323PP 20000630
 AU 2001073094 A5 20020114 AU 2001-73094 20010629
 US 2000-215323PP 20000630
 WO 2001-US20856W 20010629
 US 2002016320 A1 20020207 US 2001-896874 20010629
 US 2000-215323PP 20000630
 FAN 2002:31410
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2002002520 A2 20020110 WO 2001-US21000 20010702
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ,
 TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2000-215323PP 20000630
 US 2001-895843 A 20010629
 AU 2001073132 A5 20020114 AU 2001-73132 20010702
 US 2000-215323PP 20000630
 US 2001-895843 A 20010629
 WO 2001-US21000W 20010702
 OS MARPAT 136:102189
 GI



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.;
 R2 = H, (un)substituted alkyl; R3 = H, (un)substituted alkyl; or R2 and R3

are taken together with the carbon to which they are attached to form (un)substituted 3-7 membered carbo(or hetero)cycle; R4 = RX; X = CO, SO2; R = Ph, naphthyl, indanyl, etc.; R5 = alkyl, (CH2)0-3cycloalkyl, etc.], useful as .beta.-secretase inhibitors, were prepd. Thus, reacting (2S,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate with N,N,-dipropylamidoisophthalic acid in the presence of Et3N, HOBt and EDC in CH2Cl2 afforded (1S,2S)-II.

IT 388077-90-5P 388077-91-6P 388077-92-7P
388077-93-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted amines for treating Alzheimer's disease)

RN 388077-90-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2S)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(3-methoxyphenyl)methyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-91-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2S)-1-[(3,5-difluorophenyl)methyl]-3-(hexylamino)-2-hydroxypropyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388077-92-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2S)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 8 OF 20 USPATFULL

ACCESSION NUMBER: 2002:27472 USPATFULL

TITLE: Compounds to treat alzheimer's disease

INVENTOR(S): Fang, Lawrence Y., Foster City, CA, UNITED STATES

John, Varghese, San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002016320	A1	20020207
APPLICATION INFO.:	US 2001-896874	A1	20010629 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215323P	20000630 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	147	
EXEMPLARY CLAIM:	1	
LINE COUNT:	12236	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is substituted amines of formula (XV) ##STR1##

useful in treating Alzheimer's ease and other similar dise

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 388083-43-0 388083-44-1 388083-45-2

(comps. to treat Alzheimer's disease and other cognitive impairment disorders in relation to inhibition of .beta.-secretase and cleavage of amyloid precursor protein and combination with other agents)


RN 388083-43-0 USPATFULL

CN 1,3-Benzenedicarboxamide, N'-[1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-(2-methyl-2-phenylhydrazino)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

App 21

Fritz, James E., Greenwoode, IN, UNITED STATES
Hammond, Marlys, Pasadena, CA, UNITED STATES
Hornback, William J., Indianapolis, IN, UNITED STATES
Kaldor, Stephen W., Indianapolis, IN, UNITED STATES
Kalish, Vincent J., San Diego, CA, UNITED STATES
Munroe, John E., Indianapolis, IN, UNITED STATES
Reich, Siegfried Heinz, San Diego, CA, UNITED STATES
Tatlock, John H., Poway, CA, UNITED STATES
Shepherd, Timothy A., Indianapolis, IN, UNITED STATES
Rodriguez, Michael J., Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002077338	A1	20020620
APPLICATION INFO.:	US 2001-885056	A1	20010621 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-663348, filed on 15 Sep 2000, PENDING Continuation of Ser. No. US 1999-283152, filed on 1 Apr 1999, GRANTED, Pat. No. US 6162812 Continuation of Ser. No. US 1995-481831, filed on 7 Jun 1995, GRANTED, Pat. No. US 5952343 Continuation of Ser. No. US 1994-190764, filed on 2 Feb 1994, GRANTED, Pat. No. US 5484926 Continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, ABANDONED Continuation-in-part of Ser. No. US 1993-133696, filed on 7 Oct 1993, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6365		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
IT	167299-61-8P (prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)		
RN	167299-61-8 USPATFULL		
CN	1,3-Benzenedicarboxamide, N3-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)		
Absolute stereochemistry.			



AB Title compds. RRONCOZCONHCH(CH₂R₁)CHOHCH₂X (R, R₀ = H, C₁-6 alkyl, aryl-C₁-4 alkyl, heterocyclyl-C₁-4 alkyl, RRON = heterocyclyl with the proviso that the N may not be quaternized; Z = (substituted) phenylene, (substituted) heterocyclidiyl; R₁ = aryl, (unsatd) heterocyclyl, C₅-7 cycloalkyl, arylthio, heterocyclylthio, C₅-7 cycloalkylthio; X = (substituted)aryl, (substituted)unsatd. heterocyclyl, etc.) or a pharmaceutically salt thereof, are prepd. DCC, hydroxybenztriazole, 2-[2'-N-(methylaza)-3'-oxo-3'-(3"-carboxy-4"-methylphenyl)propyl]quinoline and [3S-(3R,4aR,8aR,2'S,3'R)]-2-[3'-amino-2'-hydroxy-4'-phenyl]butyldecahydroisoquinoline-3-N-tert-butylcarboxamide in THF/DMF were reacted to give title compd. I. In fluorescence HIV-1 protease inhibitor assay the IC₅₀ of I was 0.7 ng/mL. Pharmaceutical formulations comprising the title compds. are given.


IT **167299-61-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 7 OF 20 USPATFULL

ACCESSION NUMBER: 2002:149182 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Dressman, Bruce A., Indianapolis, IN, UNITED STATES

US 5846993	A	19981208	US 1993-133696 B219931007
			US 1993-137254 B219931018
			US 1994-190764 A319940202
			US 1995-481833 19950607
			US 1992-995621 B219921222
			US 1993-133543 B219931007
			US 1993-137254 B219931018
US 5852043	A	19981222	US 1994-190764 A319940202
			US 1995-484706 19950607
			US 1992-995621 B219921222
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1993-137254 B219931018
US 5859002	A	19990112	US 1994-190764 A319940202
			US 1995-474138 19950607
			US 1992-995621 B219921222
			US 1993-133543 B219931007
			US 1993-133696 A219931007
			US 1993-137254 B219931018
US 5952343	A	19990914	US 1994-190764 A319940202
			US 1995-481831 19950607
			US 1992-995621 B219921222
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1993-137254 B219931018
US 6271235	B1	20010807	US 1994-190764 A119940202
			US 1995-478600 19950607
			US 1992-995621 B219921222
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1993-137254 B219931018
FI 9601449	A	19960529	US 1994-190764 A319940202
			FI 1996-1449 19960329
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
NO 9601382	A	19960409	WO 1994-US11307W 19941007
			NO 1996-1382 19960403
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
US 6162812	A	20001219	WO 1994-US11307W 19941007
			US 1999-283152 19990401
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1994-190764 A119940202
CN 1262272	A	20000809	US 1995-481831 A119950607
			CN 1999-105164 19990426
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
US 2002077338	A1	20020620	US 1994-190764 A 19940202
			US 2001-885056 20010621
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1994-190764 A119940202
			US 1995-481831 A119950607
			US 1999-283152 A119990401
			US 2000-663348 A320000915

OS MARPAT 123:169523
GI

-----R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT

			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			EP 1994-930609 A319941007
RU 2139280	C1	19991010	RU 1996-109378 19941007
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			WO 1994-US11307W 19941007
JP 11310573	A2	19991109	JP 1999-67231 19941007
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			JP 1995-511006 A319941007
CZ 290417	B6	20020717	CZ 1996-1004 19941007
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
AT 222240	E	20020815	AT 1994-930609 19941007
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			WO 1994-US11307W 19941007
IL 125098	A1	20000131	IL 1994-125098 19941031
			US 1994-190764 A 19940202
			IL 1994-111472 A319941031
IL 111472	A1	20000601	IL 1994-111472 19941031
			US 1994-190764 A 19940202
TW 432049	B	20010501	TW 1994-83110782 19941119
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
US 5824688	A	19981020	US 1995-473363 19950607
			US 1992-995621 B219921222
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1993-137254 B219931018
			US 1994-190764 A319940202
US 5827858	A	19981027	US 1995-478020 19950607
			US 1992-995621 B219921022
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1993-137254 B219931018
			US 1994-190764 A319940202
US 5827891	A	19981027	US 1995-478599 19950607
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1994-190764 A319940202
US 5827859	A	19981027	US 1995-478934 19950607
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1994-190764 A319940202
US 5834467	A	19981110	US 1995-482504 19950607
			US 1992-995621 B219921222
			US 1993-133543 B219931007
			US 1993-133696 B219931007
			US 1993-137254 B219931018
			US 1994-190764 A319940202
US 5837710	A	19981117	US 1995-479765 19950607
			US 1992-995621 B219921222
			US 1993-133543 B219931007


			US 1994-190764 A 19940202
			WO 1994-US11307W 19941007
NO 9601382	A	19960409	NO 1996-1382 19960403
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			WO 1994-US11307W 19941007
FAN 1996:106715			
PATENT NO.	KIND	DATE	APPLICATION NO. DATE
-----	----	-----	-----
PI US 5484926	A	19960116	US 1994-190764 19940202
			US 1993-133543 B219931007
			US 1993-133696 B219931007
ZA 9407815	A	19960708	ZA 1994-7815 19941006
			US 1993-133543 A 19931007
CA 2173328	AA	19950413	CA 1994-2173328 19941007
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
WO 9509843	A1	19950413	WO 1994-US11307 19941007
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN			
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
AU 9479674	A1	19950501	AU 1994-79674 19941007
AU 694746	B2	19980730	
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			WO 1994-US11307W 19941007
EP 722439	A1	19960724	EP 1994-930609 19941007
EP 722439	B1	20020814	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			WO 1994-US11307W 19941007
CN 1131942	A	19960925	CN 1994-193534 19941007
CN 1046269	B	19991110	
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
JP 09501443	T2	19970210	JP 1994-511006 19941007
JP 2951724	B2	19990920	
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			WO 1994-US11307W 19941007
BR 9407782	A	19970318	BR 1994-7782 19941007
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
			WO 1994-US11307W 19941007
HU 75652	A2	19970528	HU 1996-908 19941007
			US 1993-133543 A 19931007
			US 1993-133696 A 19931007
			US 1994-190764 A 19940202
EP 889036	A1	19990107	EP 1998-113006 19941007

JP 06256277	A2	19940913	JP 1993-321876	19931221
			US 1992-995621 A	19921222
CN 1092410	A	19940921	CN 1993-112960	19931221
			US 1992-995621 A	19921222
BR 9305161	A	19941101	BR 1993-5161	19931221
			US 1992-995621 A	19921222

PATENT FAMILY INFORMATION:


FAN 1995:851692

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9509843	A1	19950413	WO 1994-US11307	19941007
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1993-133543 A	19931007
				US 1993-133696 A	19931007
				US 1994-190764 A	19940202
US 5484926	A	19960116	US 1994-190764	19940202	
			US 1993-133543 B2	19931007	
			US 1993-133696 B2	19931007	
ZA 9407815	A	19960708	ZA 1994-7815	19941006	
			US 1993-133543 A	19931007	
AU 9479674	A1	19950501	AU 1994-79674	19941007	
AU 694746	B2	19980730			
			US 1993-133543 A	19931007	
			US 1993-133696 A	19931007	
			US 1994-190764 A	19940202	
			WO 1994-US11307W	19941007	
EP 722439	A1	19960724	EP 1994-930609	19941007	
EP 722439	B1	20020814			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			US 1993-133543 A	19931007	
			US 1993-133696 A	19931007	
			US 1994-190764 A	19940202	
			WO 1994-US11307W	19941007	
JP 09501443	T2	19970210	JP 1994-511006	19941007	
JP 2951724	B2	19990920			
			US 1993-133543 A	19931007	
			US 1993-133696 A	19931007	
			US 1994-190764 A	19940202	
			WO 1994-US11307W	19941007	
BR 9407782	A	19970318	BR 1994-7782	19941007	
			US 1993-133543 A	19931007	
			US 1993-133696 A	19931007	
			US 1994-190764 A	19940202	
			WO 1994-US11307W	19941007	
RU 2139280	C1	19991010	RU 1996-109378	19941007	
			US 1993-133543 A	19931007	
			US 1993-133696 A	19931007	
			US 1994-190764 A	19940202	
			WO 1994-US11307W	19941007	
AT 222240	E	20020815	AT 1994-930609	19941007	
			US 1993-133543 A	19931007	
			US 1993-133696 A	19931007	
			US 1994-190764 A	19940202	
			WO 1994-US11307W	19941007	
FI 9601449	A	19960529	FI 1996-1449	19960329	
			US 1993-133543 A	19931007	
			US 1993-133696 A	19931007	




RN 388077-93-8 CAPLUS
 CN 1,3-Benzenedicarboxamide, N'-[(1S,2S)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]propyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L26 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2002 ACS
 AN 1995:772556 CAPLUS
 DN 123:169523
 TI Preparation of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS
 IN Dressman, Bruce A.; Hammond, Marlys; Kaldor, Stephen W.
 PA Lilly, Eli, and Co., USA
 SO Can. Pat. Appl., 147 pp.
 CODEN: CPXXEB
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2112052	AA	19940623	CA 1993-2112052	19931221
				US 1992-995621 A	19921222
	NO 9304721	A	19940623	NO 1993-4721	19931220
				US 1992-995621 A	19921222
	AU 9352529	A1	19940707	AU 1993-52529	19931220
				US 1992-995621 A	19921222
	EP 609625	A1	19940810	EP 1993-310355	19931220
				R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE	
				US 1992-995621 A	19921222
	HU 69703	A2	19950928	HU 1993-3677	19931220
				US 1992-995621 A	19921222
	FI 9305780	A	19940623	FI 1993-5780	19931221
				US 1992-995621 A	19921222




RN 388083-44-1 USPATFULL

CN Pentanoic acid, 4-methyl-, 2-[4-(3,5-difluorophenyl)-3-[[3-
[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]-2-hydroxybutyl]-1-
methylhydrazide (9CI) (CA INDEX NAME)



RN 388083-45-2 USPATFULL

CN 1,3-Benzenedicarboxamide, N'-[1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-
(phenoxyamino)propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



L26 ANSWER 9 OF 20 USPATFULL

ACCESSION NUMBER: 2001:125997 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Dressman, Bruce A., Indianapolis, IN, United States
Fritz, James E., McCordsville, IN, United States
Kaldor, Stephen W., Indianapolis, IN, United States
Kalish, Vincent J., San Diego, CA, United States
Reich, Siegfried Heinz, Solana Beach, CA, United States
Rodriguez, Michael J., Indianapolis, IN, United States
Shepherd, Timothy A., Indianapolis, IN, United States
Tatlock, John H., Vista, CA, United States
Jungheim, Louis Nickolaus, Indianapolis, IN, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6271235	B1	20010807
APPLICATION INFO.:	US 1995-478600		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926		
	Continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned		
	Continuation-in-part of Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned		
	Continuation-in-part of Ser. No. US 1993-137254, filed on 18 Oct 1993, now abandoned		
	Continuation-in-part of Ser. No. US 1992-995621, filed on 22 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Seaman, D. Margaret		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6593		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[[[1,1-dimethylethyl]amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 10 OF 20 USPATFULL

ACCESSION NUMBER: 2000:171036 USPATFULL

TITLE: Pharmaceutical compositions containing HIV protease inhibitors and methods of their use

INVENTOR(S): Dressman, Bruce A., Indianapolis, IN, United States
Fritz, James E., Greenwoode, IN, United States

Searched by Barb O'Bryen, STIC 308-4291

Hammond, Marlys, Pasadena, CA, United States
 Hornback, William J., Indianapolis, IN, United States
 Kaldor, Stephen W., Indianapolis, IN, United States
 Kalish, Vincent J., San Diego, CA, United States
 Munroe, John E., Indianapolis, IN, United States
 Reich, Siegfried Heinz, San Diego, CA, United States
 Tatlock, John H., Poway, CA, United States
 Shepherd, Timothy A., Indianapolis, IN, United States
 Rodriguez, Michael J., Indianapolis, IN, United States
 PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6162812		20001219
APPLICATION INFO.:	US 1999-283152		19990401 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-481831, filed on 7 Jun 1995, now patented, Pat. No. US 5952343 which is a continuation of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Seaman, D. Margaret		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6248		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 11 OF 20 USPATFULL

ACCESSION NUMBER: 1999:110333 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Dressman, Bruce A., Indianapolis, IN, United States
Fritz, James E., Greenwoode, IN, United States
Hornback, William J., Indianapolis, IN, United States
Kaldor, Stephen W., Indianapolis, IN, United States
Kalish, Vincent J., San Diego, CA, United States
Munroe, John E., Indianapolis, IN, United States
Reich, Siegfried Heinz, San Diego, CA, United States
Tatlock, John H., Poway, CA, United States
Shepherd, Timothy A., Indianapolis, IN, United States
Rodriguez, Michael J., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5952343		19990914
APPLICATION INFO.:	US 1995-481831		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 And a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-137254, filed on 18 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995621, filed on 22 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	M. Mach, D. Margaret		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6331		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 12 OF 20 USPATFULL

ACCESSION NUMBER: 1999:4659 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Kalish, Vincent J., San Diego, CA, United States

Reich, Siegfried H., San Diego, CA, United States

Tatlock, John H., Poway, CA, United States

Rodriguez, Michael J., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5859002		19990112
APPLICATION INFO.:	US 1995-474138		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned And Ser. No. US 1993-133696, filed on 7 Oct 1993, now patented, Pat. No. US 5497934 And a continuation-in-part of Ser. No. US 1993-137254, filed on 18 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995621, filed on 22 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Mach, D. Margaret M.		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6422		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally

other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 13 OF 20 USPATFULL

ACCESSION NUMBER: 1998:159973 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Kalish, Vincent J., San Diego, CA, United States
Reich, Siegfried Heinz, San Diego, CA, United States
Tatlock, John H., Poway, CA, United States
Rodriguez, Michael J., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5852043		19981222
APPLICATION INFO.:	US 1995-484706		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned And Ser. No. US 1993-137254, filed on 18 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995621, filed on 22 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Mach, D. Margaret M.		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6106		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 14 OF 20 USPATFULL

ACCESSION NUMBER: 1998:154300 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Dressman, Bruce A., Indianapolis, IN, United States
Fritz, James E., Greenwoode, IN, United States
Kaldor, Stephen W., Indianapolis, IN, United States
Kalish, Vincent J., San Diego, CA, United States
Reich, Siegfried Heinz, San Diego, CA, United States
Tatlock, John H., Poway, CA, United States
Rodriguez, Michael J., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5846993		19981208
APPLICATION INFO.:	US 1995-481833		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned And Ser. No. US 1993-137254, filed on 18 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995621, filed on 22 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		

ASSISTANT EXAMINER: Mach, D. Margaret M.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 6141

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPTFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 15 OF 20 USPTFULL

ACCESSION NUMBER: 1998:144109 USPTFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Hornback, William J., Indianapolis, IN, United States

Kalish, Vincent J., San Diego, CA, United States

Munroe, John E., Indianapolis, IN, United States

Reich, Siegfried Heinz, San Diego, CA, United States

Tatlock, John H., Poway, CA, United States

Shepherd, Timothy A., Indianapolis, IN, United States

Rodriguez, Michael J., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837710		19981117
APPLICATION INFO.:	US 1995-479765		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned Ser. No. Ser. No. US		

Searched by Barb O'Bryen, STIC 308-4291

1993-133696, filed on 7 Oct 1993, now abandoned And
Ser. No. US 1993-137254, filed on 18 Oct 1993, now
abandoned which is a continuation-in-part of Ser. No.
US 1992-995621, filed on 22 Dec 1992, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Mach, D. Margaret M.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 6408
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*)],3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 16 OF 20 USPATFULL

ACCESSION NUMBER: 1998:138900 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Kalish, Vincent J., San Diego, CA, United States
Dressman, Bruce A., Indianapolis, IN, United States
Fritz, James E., Greenwoode, IN, United States
Hammond, Marlys, Pasadena, CA, United States
Hornback, William J., Indianapolis, IN, United States
Kaldor, Stephen W., Indianapolis, IN, United States
Munroe, John E., Indianapolis, IN, United States
Reich, Siegfried Heinz, San Diego, CA, United States
Tatlock, John H., Poway, CA, United States
Shepherd, Timothy A., Indianapolis, IN, United States
Rodriquez, Michael J., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834467		19981110
APPLICATION INFO.:	US 1995-482504		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned Ser. No. Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned And Ser. No. US 1993-137254, filed on 18 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995621, filed on 22 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Mach, D. Margaret M.		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6159		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*)],3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 17 OF 20 USPATFULL

ACCESSION NUMBER: 1998:131753 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Dressman, Bruce A., Indianapolis, IN, United States
Fritz, James E., Greenwoode, IN, United States
Hammond, Marlys, Pasadena, CA, United States
Hornback, William J., Indianapolis, IN, United States
Kaldor, Stephen W., Indianapolis, IN, United States
Kalish, Vincent J., San Diego, CA, United States
Munroe, John E., Indianapolis, IN, United States
Reich, Siegfried Heinz, San Diego, CA, United States
Tatlock, John H., Poway, CA, United States
Shepherd, Timothy A., Indianapolis, IN, United States
Rodriguez, Michael J., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5827891		19981027
APPLICATION INFO.:	US 1995-478599		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned And Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Mach, D. Margaret M.		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6374		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 18 OF 20 USPATFULL

ACCESSION NUMBER: 1998:131724 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Kalish, Vincent J., San Diego, CA, United States
 Reich, Siegfried Heinz, San Diego, CA, United States
 Rodriguez, Michael J., Indianapolis, IN, United States
 Tatlock, John H., Poway, CA, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5827859		19981027
APPLICATION INFO.:	US 1995-478934		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned Ser. No. Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Mach, D. Margaret M.		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6223		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinoliny]]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 19 OF 20 USPATFULL

ACCESSION NUMBER: 1998:131723 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Kalish, Vincent J., San Diego, CA, United States
 Reich, Siegfried Heinz, San Diego, CA, United States
 Tatlock, John H., Poway, CA, United States
 Rodriguez, Michael J., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5827858		19981027
APPLICATION INFO.:	US 1995-478020		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned Ser. No. Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned And Ser. No. US 1993-137254, filed on 18 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995621, filed on 22 Oct 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Mach, D. Margaret M.		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6401		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 167299-61-8P


(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]oct

ahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 20 OF 20 USPATFULL

ACCESSION NUMBER: 1998:128276 USPATFULL

TITLE: HIV protease inhibitors

INVENTOR(S): Kalish, Vincent J., San Diego, CA, United States
Reich, Siegfried Heinz, San Diego, CA, United States
Tatlock, John H., Poway, CA, United States
Rodriguez, Michael J., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824688		19981020
APPLICATION INFO.:	US 1995-473363		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-190764, filed on 2 Feb 1994, now patented, Pat. No. US 5484926 which is a continuation-in-part of Ser. No. US 1993-133543, filed on 7 Oct 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-133696, filed on 7 Oct 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-137254, filed on 18 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995621, filed on 22 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Mach, D. Margaret M.		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6437		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 167299-61-8P

(prepn. of heterocycle amides as inhibitors of HIV protease useful for treatment of AIDS)

RN 167299-61-8 USPATFULL

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinoliny]-2-hydroxy-1-(phenylmethyl)propyl]-N1,N1,4-trimethyl-, [3S-[2(1R*,2S*),3.alpha.,4a.beta.,8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil cao; d que nos l11

FILE 'CAOLD' ENTERED AT 15:30:58 ON 26 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L1 STR
L2 SCR 1834
L3 11310 SEA FILE=REGISTRY SSS FUL L1 AND L2
L4 STR
L8 593 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L11 0 SEA FILE=CAOLD ABB=ON L8

=> fil capl; d que 125; s 125 not 19
FILE 'CAPLUS' ENTERED AT 15:30:27 ON 26 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2002 VOL 137 ISS 13
FILE LAST UPDATED: 25 Sep 2002 (20020925/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L12 STR



NODE ATTRIBUTES:

NSPEC	IS	RC	AT	1
NSPEC	IS	RC	AT	4
NSPEC	IS	RC	AT	5
NSPEC	IS	RC	AT	6

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L13 SCR 1834

L14 (11310)SEA FILE=REGISTRY SSS FUL L12 AND L13
L15 (2306)SEA FILE=CAPLUS ABB=ON L14
L16 (23419)SEA FILE=CAPLUS ABB=ON ?ALZHEIMER?
L17 (461)SEA FILE=CAPLUS ABB=ON (COGNIT?(L)IMPAIR?)/OBI
L18 (1867)SEA FILE=CAPLUS ABB=ON DOWN?(L)SYNDROME/OBI
L19 (12911)SEA FILE=CAPLUS ABB=ON AMYLOID?/OBI
L20 (4426)SEA FILE=CAPLUS ABB=ON (DEMENT? OR ANTIDEMENT?)/OBI
L21 (15101)SEA FILE=CAPLUS ABB=ON ?PARKINSON?
L22 (115)SEA FILE=CAPLUS ABB=ON SUPRANUCLEAR(L)PALS?/OBI
L23 (129)SEA FILE=CAPLUS ABB=ON CORTICAL(L)BASAL/OBI
L24 (468)SEA FILE=CAPLUS ABB=ON LEWY/OBI

*Same full file search
as before*

method search

L25 36 SEA FILE=CAPLUS ABB=ON- L15 AND (L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24)

L27 31 L25 NOT (L9) *previously printed*

=>d fbib abs hitstr 127 1-31; fil hom

L27 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2002:638144 CAPLUS

DN 137:163841

TI Methods for regulating levels of zinc, cadmium, and calcium in humans and for diagnosing, or screening for the risk of developing diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues

IN Woods, Gordon L.

PA USA

SO U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. Ser. No. 610,538, abandoned.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002114848	A1	20020822	US 2001-989674	20011121
				US 1999-142926PP	19990709
				US 2000-610538	B220000707

PATENT FAMILY INFORMATION:

FAN 2001:50495

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001003708	A1	20010118	WO 2000-US18580	20000707
	W: CA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1999-142926PP	19990709
EP 1200104	A1	20020502	EP 2000-947094	20000707	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
				US 1999-142926PP	19990709
				WO 2000-US18580W	20000707

AB Methods and compns. are provided for decreasing PGE2:PGF2.alpha., regulating ratios of zinc:cadmium and regulating the concn. of zinc, calcium and zinc-contg. and PGE2-dependent matrix metalloproteinases in body fluids and tissues of a human. Elevated or otherwise unregulated levels of PGE2, zinc and calcium and elevated concns. of zinc-contg. and PGE2-dependent matrix metalloproteinases have been found to be assocd. with the development of certain diseases. Methods for the prevention of a variety of diseases are also disclosed.

IT 149845-06-7, Invirase 159989-65-8, Nelfinavir mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(zinc, cadmium, and calcium level regulation in humans, and use in disease diagnosis and prevention)


RN 149845-06-7 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[1,1-dimethylethyl]amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 127779-20-8
CMF C38 H50 N6 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 159989-65-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 159989-64-7
CMF C32 H45 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



L27 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2002:533948 CAPLUS
DN 137:88472
TI TNF modulators for treating neurological disorders associated with viral infection
IN Tobinick, Edward L.
PA USA
SO U.S., 10 pp., Cont.-in-part of U. S. Ser. No. 563,651.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6419934	B1	20020716	US 2000-654996	20000905
				US 1999-256388	B219990224
				US 1999-275070	A219990323
				US 1999-476643	A219991231
				US 2000-563651	A220000502
	US 6015557	A	20000118	US 1999-275070	19990323
				US 1999-256388	B219990224
	US 6177077	B1	20010123	US 1999-476643	19991231
				US 1999-256388	B219990224
				US 1999-275070	A219990323
	US 2001004456	A1	20010621	US 2000-749189	20001227
	US 6423321	B1	20020723		
				US 1999-256388	B219990224
				US 1999-275070	A219990323
				US 1999-476643	A219991231
				US 2000-563651	A220000502
				US 2000-654996	A220000905
	US 2002131954	A1	20020919	US 2002-152476	20020523
				US 2000-563651	A320000502
	US 2002131955	A1	20020919	US 2002-152477	20020523
				US 2000-563651	A320000502

PATENT FAMILY INFORMATION:

FAN 2000:46917

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6015557	A	20000118	US 1999-275070	19990323
				US 1999-256388	B219990224
	US 6177077	B1	20010123	US 1999-476643	19991231
				US 1999-256388	B219990224
				US 1999-275070	A219990323
WO	2000050079	A1	20000831	WO 2000-US1148	20000117

W: AE, AL, AM, AT, AU, BA, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, KZ, LK, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, TR, UA, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE


EP 1161260	A1	20011212	US 1999-256388 A 19990224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LV, FI, RO			US 1999-275070 A 19990323
			EP 2000-904395 20000117
US 6419934	B1	20020716	US 1999-256388 A 19990224
			US 1999-275070 A 19990323
			WO 2000-US1148 W 20000117
			US 2000-654996 20000905
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
US 2001004456	A1	20010621	US 2000-563651 A220000502
US 6423321	B1	20020723	US 2000-749189 20001227
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
US 2001016195	A1	20010823	US 2000-654996 A220000905
US 6419944	B2	20020716	US 2001-826976 20010405
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
US 2001026801	A1	20011004	US 2001-841844 20010425
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
			US 2001-826976 A220010405
FAN 2001:58562			
PATENT NO.	KIND	DATE	APPLICATION NO. DATE
-----	----	-----	-----
PI US 6177077	B1	20010123	US 1999-476643 19991231
			US 1999-256388 B219990224
US 6015557	A	20000118	US 1999-275070 A219990323
			US 1999-275070 19990323
US 6419934	B1	20020716	US 1999-256388 B219990224
			US 2000-654996 20000905
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
US 6428787	B1	20020806	US 2000-563651 A220000502
			US 2000-665529 20000919
			US 1999-256388 B219990224
US 6379666	B1	20020430	US 1999-476643 A319991231
			US 2000-666068 20001211
			US 1999-256388 B219990224
US 2001004456	A1	20010621	US 1999-476643 A319991231
US 6423321	B1	20020723	US 2000-749189 20001227
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
			US 2000-654996 A220000905
WO 2001049321	A1	20010712	WO 2000-US35464 20001228
W: AE, AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DZ, EE, ES, FI, GB, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, KZ, LT, LU, LV, MK, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI,			

SK, TJ, TM, TR, TZ, UA, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, ---
 MD, RU, TJ, TM
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, TR

US 2001016195	A1	20010823	US 1999-476643 A 19991231
US 6419944	B2	20020716	US 2001-826976 20010405
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
US 2001026801	A1	20011004	US 2001-841844 20010425
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
			US 2001-826976 A220010405
FAN 2001:453452			
PATENT NO.	KIND	DATE	APPLICATION NO. DATE
-----	-----	-----	-----
PI US 2001004456	A1	20010621	US 2000-749189 20001227
US 6423321	B1	20020723	
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
			US 2000-654996 A220000905
US 6015557	A	20000118	US 1999-275070 19990323
			US 1999-256388 B219990224
US 6177077	B1	20010123	US 1999-476643 19991231
			US 1999-256388 B219990224
			US 1999-275070 A219990323
US 6419934	B1	20020716	US 2000-654996 20000905
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
US 2002131954	A1	20020919	US 2002-152476 20020523
			US 2000-563651 A320000502
US 2002131955	A1	20020919	US 2002-152477 20020523
			US 2000-563651 A320000502
FAN 2001:618414			
PATENT NO.	KIND	DATE	APPLICATION NO. DATE
-----	-----	-----	-----
PI US 2001016195	A1	20010823	US 2001-826976 20010405
US 6419944	B2	20020716	
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
US 6015557	A	20000118	US 1999-275070 19990323
			US 1999-256388 B219990224
US 6177077	B1	20010123	US 1999-476643 19991231
			US 1999-256388 B219990224
			US 1999-275070 A219990323
US 2001026801	A1	20011004	US 2001-841844 20010425
			US 1999-256388 B219990224
			US 1999-275070 A219990323
			US 1999-476643 A219991231
			US 2000-563651 A220000502
			US 2001-826976 A220010405
US 2002131954	A1	20020919	US 2002-152476 20020523
			US 2000-563651 A320000502

	US 2002131955	A1	20020919	US 2002-152477	20020523
				US 2000-563651	A320000502
FAN	2001:731315				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2001026801	A1	20011004	US 2001-841844	20010425
				US 1999-256388	B219990224
				US 1999-275070	A219990323
				US 1999-476643	A219991231
				US 2000-563651	A220000502
				US 2001-826976	A220010405
	US 6015557	A	20000118	US 1999-275070	19990323
				US 1999-256388	B219990224
	US 6177077	B1	20010123	US 1999-476643	19991231
				US 1999-256388	B219990224
				US 1999-275070	A219990323
	US 2001016195	A1	20010823	US 2001-826976	20010405
	US 6419944	B2	20020716		
				US 1999-256388	B219990224
				US 1999-275070	A219990323
				US 1999-476643	A219991231
				US 2000-563651	A220000502
	US 2002131954	A1	20020919	US 2002-152476	20020523
				US 2000-563651	A320000502
	US 2002131955	A1	20020919	US 2002-152477	20020523
				US 2000-563651	A320000502
AB	The invention discloses a method for inhibiting the action of TNF for treating neurol. conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue or for modulating the immune response affecting neuronal tissue of a human subject. This is accomplished by administering a therapeutically effective dosage level of TNF antagonist selected from the group consisting of etanercept, infliximab, and D2E7 (a human anti-TNF mAb from Knoll Pharmaceuticals) to the human subject. In addn., for the viral-assocd. neurol. disorders, the following addnl. step is performed: administering a therapeutically effective dosage level of an antiviral agent or anti-retroviral agents to the human subject.				
IT	127779-20-8, Saquinavir 159989-64-7, Nelfinavir 161814-49-9, Amprenavir				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(TNF modulators for treating neurol. disorders assocd. with viral infection)				
RN	127779-20-8 CAPLUS				
CN	Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 159989-64-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161814-49-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2002:450341 CAPLUS

DN 137:15765

TI Use of Iron and Manganese complexes for preventing and treating
HIV-mediated central nervous system damage

IN Salvemini, Daniela

PA Metaphore Pharmaceuticals, Inc, USA
SO U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002072512	A1	20020613	US 2001-951855	20010913
				US 2000-254405PP	20001208

OS MARPAT 137:15765

AB The invention relates to methods of preventing and/or treating HIV-mediated central nervous system damage. The method comprises administering therapeutic amts. of non-proteinaceous catalysts for the dismutation of superoxide to a subject either alone or in combination with a HIV anti-viral agent. The compds. of the invention are particularly suitable for treating and/or preventing AIDS Dementia Complex.


IT 147318-81-8, KNI-272

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of iron and manganese complexes for preventing and treating HIV-mediated CNS damage)

RN 147318-81-8 CAPLUS

CN 4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[(2S,3S)-2-hydroxy-3-[[[(2R)-2-[[[(5-isoquinolinyloxy)acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2002:393651 CAPLUS

DN 137:266

TI Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: Cross-sectional and longitudinal studies of event-related potentials

AU Husstedt, Ingo-W.; Frohne, Lars; Bockenholt, Sven; Frese, Achim; Rahmann, Alexandra; Heese, Christoph; Reichelt, Doris; Evers, Stefan

CS Department of Neurology, University of Munster, Munster, 48129, Germany

SO AIDS Research and Human Retroviruses (2002), 18(7), 485-490

CODEN: ARHRE7; ISSN: 0889-2229

PB Mary Ann Liebert, Inc.

DT Journal

LA English

AB Patients with HIV infection often complain of cognitive disturbances, which can be related to AIDS dementia or HIV-assocd. encephalopathy (HIVE). We investigated the impact of highly active antiretroviral

therapy (HAART) in comparison with other therapeutic regimens on the progression of these cognitive disturbances as measured by visual event-related potentials (ERP). In a cross-sectional study, 214 patients without secondary neuromanifestation of their infection were divided into four groups with respect to their treatment status for 1 yr before examn.: (1) without antiretroviral treatment, (2) zidovudine monotherapy, (3) zidovudine in combination with didanosine, zalcitabine, or lamivudine, and (4) HAART. In a prospective longitudinal study, we divided 54 patients into three groups: (1) without antiretroviral treatment, (2) zidovudine monotherapy, and (3) HAART. Latencies of the P2, N2, and P3 components and the amplitude of the P3 component were evaluated. A significant neg. correlation between CD4+ lymphocyte cell count and P3 latency was found in all patients ($p < 0.004$). In the cross-sectional study, P3 latency was significantly decreased in the HAART group as compared with patients with no antiretroviral treatment ($p < 0.01$). During the 1-yr period of the prospective longitudinal study, the P3 latency significantly increased in patients with no anti-retroviral treatment ($p < 0.05$) and significantly decreased in patients with HAART ($p < 0.05$). In summary, these results suggest that HAART has an improving therapeutic effect on cognitive processing in HIV-infected patients and is superior to zidovudine monotherapy or dual antiretroviral treatment. Because prolongation of ERP might in part reflect HIVE, we conclude that this condition represents an indication for HAART.

IT 127779-20-8, Saquinavir 159989-64-7, Nelfinavir


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HAART impact on cognitive processing tested by event-related potentials in patients with HIV-1 infection)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159989-64-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L27 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2002:153949 CAPLUS
DN 136:305914
TI Substrate and inhibitor profile of BACE (.beta.-secretase) and comparison with other mammalian aspartic proteases
AU Gruninger-Leitch, Fiona; Schlatter, Daniel; Kung, Erich; Nelbock, Peter; Dobeli, Heinz
CS CNS Research, Hoffmann-La Roche Ltd, Basel, CH-4070, Switz.
SO Journal of Biological Chemistry (2002), 277(7), 4687-4693
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB The full-length and ectodomain forms of .beta.-site APP cleavage enzyme (BACE) have been cloned, expressed in Sf9 cells, and purified to homogeneity. This aspartic protease cleaves the amyloid precursor protein at the .beta.-secretase site, a crit. step in the **Alzheimer's** disease pathogenesis. Comparison of BACE to other aspartic proteases such as cathepsin D and E, napsin A, pepsin, and renin revealed little similarity with respect to the substrate preference and inhibitor profile. On the other hand, these parameters are all very similar for the homologous enzyme BACE2. Based on a collection of decameric substrates, it was found that BACE has a loose substrate specificity and that the substrate recognition site in BACE extends over several amino acids. In common with the aspartic proteases mentioned above, BACE prefers a leucine residue at position P1. Unlike cathepsin D etc., BACE accepts polar or acidic residues at positions P2' and P1 but prefers bulky hydrophobic residues at position P3. BACE displays poor kinetic consts. toward its known substrates (wild-type substrate, SEVKM .dwnarw. DAEFR, Km = 7 .mu.M, Kcat = 0.002 s⁻¹; Swedish mutant, SEVNL .dwnarw. DAEFR, Km = 9 .mu.M, Kcat = 0.02 s⁻¹). A new substrate (VVEVDA .dwnarw. AVTP, Km = 1 .mu.M, Kcat = 0.004) was identified by serendipity.
IT 127779-20-8, Saquinavir
RL: BSU (Biological study, unclassified); BIOL (Biological study) (substrate and inhibitor profile of BACE .beta.-secretase and comparison with other mammalian aspartic proteases)
RN 127779-20-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2002:142659 CAPLUS

DN 136:184119

TI Preparation of (hydroxyethyl)ureas as inhibitors of **Alzheimer's**
.beta.-**amyloid** production

IN Wolfe, Michael S.; Selkoe, Dennis J.

PA The Brigham and Women's Hospital, Inc., USA

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014264	A2	20020221	WO 2001-US25267	20010810
	WO 2002014264	A3	20020530		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
				US 2000-225043PP	20000811
	AU 2001081250	A5	20020225	AU 2001-81250	20010810
				US 2000-225043PP	20000811
				WO 2001-US25267W	20010810
	US 2002111365	A1	20020815	US 2001-927913	20010810
				US 2000-225043PP	20000811

OS MARPAT 136:184119

GI



AB (hydroxyethyl)ureas R1NHCHR2CH(OH)CH2NR3CONHR4 [R1 is a group Q [H, alkyl, cycloalkyl or (hetero)aryl], R6O2C, R7R8NCO, where R6-R8 are selected from Q, provided that R1 is not bonded via a group CC(X) (X is O, S or N); R2, R3 = Q; NHR4 is peptidyl or R4 is selected from Q; non-hydrogen R1-R4, R6-R5 can be substituted by alkylamino, alkoxy, amino, halide, nitro, sulfate, sulfonamide, sulfoxide, or thiol ether] were prepd. for use as inhibitors of certain aspartyl proteases, notably secretases involved in the enzymic cleavage of amyloid precursor protein (APP) to yield amyloid-.beta. peptide. Methods are provided for administering the novel

compds. to treat .beta.-amyloid-assocd. diseases, notably **Alzheimer's** disease. Thus, (hydroxyethyl)urea I (Boc = tert-butoxycarbonyl) was prepd. and showed IC50 = 0.5 .mu.M for inhibition of .beta.-amyloid protein prodn. in APP751 plus neo-transfected CHO cells in vitro.

IT 398515-50-9P 398515-53-2P 398515-75-8P
 398515-82-7P 398515-89-4P 398515-96-3P
 398515-99-6P 398516-03-5P 398516-06-8P
 398516-08-0P 398516-10-4P 398516-13-7P
 399039-85-1P 399039-86-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (hydroxyethyl)ureas as inhibitors of **Alzheimer's** .beta.-amyloid prodn.)

RN 398515-50-9 CAPLUS

CN L-Leucine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl-, methyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 398515-53-2 CAPLUS

CN L-Phenylalanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-valyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398515-75-8 CAPLUS

CN L-Phenylalanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398515-82-7 CAPLUS

CN L-Phenylalanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398515-89-4 CAPLUS

CN L-Alanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398515-96-3 CAPLUS

CN L-Valine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398515-99-6 CAPLUS

CN L-Phenylalanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]carbonyl]-L-leucyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398516-03-5 CAPLUS

CN L-Phenylalanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](1-methylethyl)amino]carbonyl]-L-leucyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 398516-06-8 CAPLUS

CN L-Alanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl-L-valyl-, methyl ester (9CI) (CA INDEX NAME)

ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398516-08-0 CAPLUS

CN L-Phenylalanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl-L-valyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398516-10-4 CAPLUS


CN L-Leucine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl-L-valyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 398516-13-7 CAPLUS
 CN L-Valine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl-L-valyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 399039-85-1 CAPLUS
 CN L-Phenylalanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl]methylamino]carbonyl]-L-leucyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 399039-86-2 CAPLUS

CN L-Phenylalanine, N-[[[(2R,3S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 398516-19-3P 398516-22-8P 398516-25-1P
398516-29-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of (hydroxyethyl)ureas as inhibitors of **Alzheimer's** .beta.-amyloid prodn.)

RN 398516-19-3 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[methyl(phenylmethyl)amino]-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 398516-22-8 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(1-methylethyl)(phenylmethyl)amino]-1-

(phenylmethyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398516-25-1 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylmethyl)amino]-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 398516-29-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-bis(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2001:816447 CAPLUS

DN 135:352830

TI Methods of, and HIV protease inhibitor compounds for, inhibiting calpains, and therapeutic use thereof

IN De Petrillo, Paolo B.; Wan, Wenshuai

PA United States Dept. of Health and Human Services, USA

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001082919	A2	20011108	WO 2001-US40652	20010502
	WO 2001082919	A3	20020510		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002115665	A1	20020822	US 2000-202378PP	20000504
	US 6448245	B2	20020910	US 2001-847872	20010502
				US 2000-202378PP	20000504

OS MARPAT 135:352830

AB A method is disclosed for inhibiting calpain by contacting calpain with one or more HIV protease inhibitors or analogs. Included are embodiments for identifying subjects at risk of suffering calpain-mediated physiolo. damage and administering to them the HIV protease inhibitors or analogs. Alternatively, a compd. may be administered to a subject following an actual event implicating activation of calpain. Also included are methods of treating or preventing calpain-mediated physiolo. damage in a subject by administering to the subject a therapeutically effective amt. of a pharmaceutical compn. which includes at least one HIV protease inhibitor or analog. The pharmaceutical compns. can be used in the treatment of a variety of conditions or diseases implicated by or assocd. with calpain activation, including cardiovascular diseases.

IT 127779-20-8 127779-20-8D, esters isomers and prodrug derivs. 136522-18-4 136522-18-4D, esters isomers and prodrug derivs. 159989-64-7, Nelfinavir 161814-49-9, Amprenavir


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HIV protease inhibitors for calpain inhibition, and therapeutic use)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136522-18-4 CAPLUS

CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136522-18-4 CAPLUS

CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159989-64-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161814-49-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[4-(aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2001:676786 CAPLUS

DN 135:236448

TI .gamma.-Secretase inhibitors for treatment or prevention of


Alzheimer's disease

IN Castro Pineiro, Jose Luis; Smith, Adrian Leonard; Stevenson, Graeme Irvine
PA Merck Sharp + Dohme Limited, UK
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066564	A2	20010913	WO 2001-GB855	20010228
	WO 2001066564	A3	20020103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 2000-5251	A 20000303

OS MARPAT 135:236448

GI



AB .gamma.-Secretase-inhibiting urea derivs. I (R1 = (un)substituted C2-10 alkyl, (un)substituted C2-10 alkenyl (un)substituted C2-10 alkynyl, Ph, etc.; R2, R3 = C1-10 alkyl, C1-10 alkoxy, C2-10 alkenyl, C2-10 alkenyloxy, C2-10 alkynyl, C2-10 alkynyloxy, Ph, etc.; R,4 R5 = (un)substituted C1-6alkyl, etc.; and R5' = H, or R5 and R5' together =oxo; with proviso), and pharmaceutical salts thereof are disclosed. The invention comprises the treatment or prevention of **Alzheimer's disease**. with this novel urea derivs. (prepn. described).

IT 359840-32-7P 359840-33-8P 359840-34-9P
359840-35-0P 359840-36-1P 359840-37-2P
359840-38-3P 359840-39-4P 359840-40-7P
359840-41-8P 359840-42-9P 359840-43-0P
359840-44-1P 359840-45-2P 359840-46-3P
359840-47-4P 359840-48-5P 359840-49-6P
359840-50-9P 359840-51-0P 359840-52-1P
359840-53-2P 359840-54-3P 359840-55-4P
359840-56-5P 359840-57-6P 359840-58-7P
359849-99-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(.gamma.-secretase inhibitors for treatment or prevention of **Alzheimer's disease**)

RN 359840-32-7 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy)carbonyl]amino]butyl] (phenylmethyl)amino]carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-33-8 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy)carbonyl]amino]butyl] (2-phenylethyl)amino]carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-34-9 CAPLUS


CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy)carbonyl]amino]butyl] [2-(4-phenoxyphenyl)ethyl]amino]carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 359840-35-0 CAPLUS
CN L-Phenylalaninamide, N-[[[(4-chlorophenyl)methyl][(2R,3S)-2-hydroxy-4-phenyl-3-[[[(phenylmethoxy)carbonyl]amino]butyl]amino]carbonyl]-L-leucyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 359840-36-1 CAPLUS
CN L-Phenylalaninamide, N-[[[(3-chlorophenyl)methyl][(2R,3S)-2-hydroxy-4-phenyl-3-[[[(phenylmethoxy)carbonyl]amino]butyl]amino]carbonyl]-L-leucyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 359840-37-2 CAPLUS
CN L-Phenylalaninamide, N-[[[(2-chlorophenyl)methyl][(2R,3S)-2-hydroxy-4-phenyl-3-[[[(phenylmethoxy)carbonyl]amino]butyl]amino]carbonyl]-L-leucyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-38-3 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy) carbonyl] amino] butyl] [2-(2-pyridinyl) ethyl] amino] carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-39-4 CAPLUS

CN L-Phenylalaninamide, N-[[[(2-furanylmethyl) [(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy) carbonyl] amino] butyl] amino] carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-40-7 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-
[[(phenylmethoxy) carbonyl] amino] butyl] [[4-(trifluoromethoxy) phenyl] methyl]
amino] carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-41-8 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-
[[(phenylmethoxy) carbonyl] amino] butyl] (2-phenylethyl) amino] carbonyl]-L-
phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-42-9 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy)carbonyl]amino]butyl] (2-phenylethyl)amino]carbonyl]-L-norleucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-43-0 CAPLUS


CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy)carbonyl]amino]butyl] (2-phenylethyl)amino]carbonyl]-L-norvalyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 359840-44-1 CAPLUS
 CN L-Phenylalaninamide, (2S)-N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-
 [[(phenylmethoxy)carbonyl]amino]butyl](2-phenylethyl)amino]carbonyl]-2-
 phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 359840-45-2 CAPLUS
 CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-
 [[(phenylmethoxy)carbonyl]amino]butyl](2-phenylethyl)amino]carbonyl]-L-
 alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-46-3 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy)carbonyl]amino]butyl] (2-phenylethyl)amino]carbonyl]-L-isoleucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-47-4 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy)carbonyl]amino]butyl] (2-phenylethyl)amino]carbonyl]-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-48-5 CAPLUS

CN L-Leucinamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-
[[(phenylmethoxy) carbonyl] amino] butyl] (2-phenylethyl) amino] carbonyl]-L-
leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-49-6 CAPLUS

CN L-Norleucinamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-
[[(phenylmethoxy) carbonyl] amino] butyl] (2-phenylethyl) amino] carbonyl]-L-
leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-50-9 CAPLUS

CN L-Norvalinamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-
[(phenylmethoxy)carbonyl]amino]butyl] (2-phenylethyl) amino]carbonyl]-L-
leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-51-0 CAPLUS

CN Glycinamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-
[(phenylmethoxy)carbonyl]amino]butyl] (2-phenylethyl) amino]carbonyl]-L-
leucyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-52-1 CAPLUS

CN D-Leucinamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy) carbonyl] amino] butyl] (2-phenylethyl) amino] carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-53-2 CAPLUS

CN L-Alaninamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy) carbonyl] amino] butyl] (2-phenylethyl) amino] carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 359840-54-3 CAPLUS

CN L-Isoleucinamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-

[[(phenylmethoxy) carbonyl] amino] butyl]-(2-phenylethyl) amino] carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-55-4 CAPLUS

CN L-Valinamide, N-[[[(2R,3S)-2-hydroxy-4-phenyl-3-[[(phenylmethoxy) carbonyl] amino] butyl] (2-phenylethyl) amino] carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-56-5 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl] amino] carbonyl] (2-phenylethyl) amino]-2-hydroxy-1-(phenylmethyl)propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-57-6 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl](2-phenylethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359840-58-7 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(1S,2S)-1-(aminocarbonyl)-2-methylbutyl]amino]carbonyl](2-phenylethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359849-99-3 CAPLUS

CN L-Phenylalaninamide, N-[[[(2R,3S)-3-[[[1,1-dimethylethoxy]carbonyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]carbonyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	WO 2001032928	A3	20020725		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 1999-165398PP 19991105

US 2000-196571PP 20000411


AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

IT 127779-20-8, Saquinavir 161814-49-9, Amprenavir
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[1,1-dimethylethyl]amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161814-49-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[4-aminophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2001:137173 CAPLUS

DN 134:178396

TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
	WO 2001012584	A3	20020829		
	W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000013264	A	20020416	IT 1999-MI1817 A	19990812
				BR 2000-13264	20000727
				IT 1999-MI1817 A	19990812
				WO 2000-EP7225 W	20000727
	NO 2002000623	A	20020409	NO 2002-623	20020208
				IT 1999-MI1817 A	19990812
				WO 2000-EP7225 W	20000727

OS MARPAT 134:178396

AB Compds. or their salts of general formula (I): A-B-N(O)_s wherein: s is an integer equal to 1 or 2; A = R-Tl-, wherein R is the drug radical and Tl = (CO)_t or (X)_{t'}, wherein X = O, S, NR_{1c}, R_{1c} is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB -X₂-O- wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X₂, bivalent radical, is such that the precursor drug of A and the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

IT 127779-20-8, Saquinavir

RL: RCT (Reactant); RACT (Reactant or reagent)


(antiviral; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[1,1-dimethylethyl]amino]carbonyl]octahydro-2(1H)-isoquinoliny]]-2-hydroxy-1-

(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:742057 CAPLUS

DN 133:309791

TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000061541	A2	20001019	WO 2000-EP3239	20000411
WO 2000061541	A3	20010927		
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
IT 1311923	B1	20020320	IT 1999-MI752	A 19990413
BR 2000009703	A	20020108	IT 1999-MI752	19990413
			BR 2000-9703	20000411
			IT 1999-MI752	A 19990413
			WO 2000-EP3239	W 20000411
EP 1169298	A2	20020109	EP 2000-926870	20000411
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
			IT 1999-MI752	A 19990413
			WO 2000-EP3239	W 20000411
NO 2001004928	A	20011213	NO 2001-4928	20011010
			IT 1999-MI752	A 19990413
			WO 2000-EP3239	W 20000411

OS MARPAT 133:309791

AB Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

IT 127779-20-8, Saquinavir


RL: RCT (Reactant); RACT (Reactant or reagent)

(antiviral; synthesis, activity and formulations of pharmaceutical
compds. for treatment of oxidative stress and/or endothelial
dysfunction)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[1,1-dimethylethylamino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:742053 CAPLUS

DN 133:310142

TI Synthesis, activity and formulations of pharmaceutical compounds for
treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
	WO 2000061537	A3	20010927		
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	IT 1311924	B1	20020320	IT 1999-MI753	A 19990413
	BR 2000009702	A	20020108	IT 1999-MI753	19990413
				BR 2000-9702	20000411
				IT 1999-MI753	A 19990413
				WO 2000-EP3234	W 20000411
EP 1169294	A2	20020109	EP 2000-925203		20000411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				IT 1999-MI753	A 19990413
				WO 2000-EP3234	W 20000411
NO 2001004927	A	20011213	NO 2001-4927		20011010
			IT 1999-MI753	A 19990413	
			WO 2000-EP3234	W 20000411	

OS MARPAT 133:310142


AB Compds. A-B-C-N(O)s and A-C1[N(O)s]-B1 or their salts [s is an integer 1 or 2, preferably s = 2; A is the radical of a drug and is such as to meet the pharmacol. tests reported in the description; C and C1 are two bivalent radicals; the precursors of the radicals B and B1 are such as to meet the pharmacol. test reported in the description] were prepd. for use as pharmaceuticals. Thus, (S,S)-N-acetyl-S-(6-methoxy-.alpha.-methyl-2-naphthalenylacetyl)cysteine 4-nitroxybutyl ester was prepd. (NCX 2101) from naproxene and N-acetylcysteine in the first of 28 synthetic examples given. Pharmacol. test examples and tabular data are also given.

IT 127779-20-8, Saquinavir
RL: RCT (Reactant); RACT (Reactant or reagent)
(drug precursor)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:688091 CAPLUS

DN 133:261535

TI Methods for treating neurodegenerative disorders using aspartyl protease inhibitors

IN Ellman, Jonathan A.; Lynch, Gary; Kuntz, Irwin D.; Bi, Xiaoning; Lee, Christina E.; Skillman, A. Geoffrey; Haque, Tasir

PA The Regents of the University of California, USA

SO PCT Int. Appl., 108 pp.
CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056335	A1	20000928	WO 2000-US7804	20000324
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW:				
	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1999-125958PP	19990324
EP 1178800	A1	20020213	EP 2000-916643	20000324	
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1999-125958PP	19990324

WO 2000-US7804 W 20000324


OS MARPAT 133:261535
AB Non-peptide aspartyl protease inhibitors, methods for modulating the processing of an amyloid precursor protein, methods for modulating the processing of a .tau.-protein, and methods for treating neurodegenerative diseases are provided.
IT 211114-74-8P 211114-75-9P 211114-76-0P 211114-94-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aspartyl protease inhibitors for modulating processing of **amyloid** precursor protein and of .tau. protein and for treating neurodegenerative disorders)
RN 211114-74-8 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxy-4-(2-naphthalenyl)butyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211114-75-9 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-4-[1,1'-biphenyl]-4-yl-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxybutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-76-0 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-4-(4-bromophenyl)-2-hydroxybutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-94-2 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxy-4-(3-phenoxyphenyl)butyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 192069-75-3 192069-78-6 192069-80-0
 192069-83-3 192069-84-4 192069-91-3
 192069-95-7 192069-96-8 192069-98-0
 192069-99-1 192070-00-1 211114-70-4
 211114-71-5 211114-77-1 211114-78-2
 211114-81-7 211114-83-9 211114-84-0
 211114-85-1 211114-86-2 211114-87-3
 211114-88-4 211114-89-5 211114-90-8
 211115-00-3 227031-04-1 227031-05-2
 227031-06-3 227031-07-4 227031-08-5
 227031-09-6 227031-10-9 227031-11-0
 227031-12-1 227031-13-2 296780-76-2
 296780-77-3 296780-78-4 296780-79-5
 296780-80-8 296780-81-9 296780-82-0
 296780-83-1 296780-84-2 296780-85-3
 296780-87-5 296780-88-6 296780-89-7
 296780-90-0 296780-92-2 296780-93-3
 296780-95-5 296780-96-6 296780-98-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aspartyl protease inhibitors for modulating processing of amyloid precursor protein and of .tau. protein and for treating neurodegenerative disorders)

RN 192069-75-3 CAPLUS
 CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-1,3-dihydro-N-[(2S,3S)-2-hydroxy-4-phenyl-3-[(2,4,5-trichlorophenoxy)acetyl]amino]butyl]-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-78-6 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[(2-chloro-3,4-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-80-0 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-83-3 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-84-4 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-91-3 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3,4-dichlorophenoxy]acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-95-7 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[[3,4-dichlorophenoxy]acetyl]amino]-2-hydroxy-4-phenylbutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-96-8 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[2,4-dichlorophenoxy]acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-98-0 CAPLUS


CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3-chlorophenoxy]acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192069-99-1 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192070-00-1 CAPLUS
CN 2H-Isoindole-2-propanamide, 1,3-dihydro-N-[(2S,3S)-2-hydroxy-4-phenyl-3-[[[(2,4,5-trichlorophenoxy)acetyl]amino]butyl]-N-[2-(4-methylphenyl)ethyl]-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211114-70-4 CAPLUS
CN Benzenepropanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-3,4-dichloro-N-[(2S,3S)-3-[(2-chloro-3,4-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-71-5 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-chloro-3,4-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-77-1 CAPLUS


CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][(2,4,6-trichlorophenoxy)acetyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 211114-78-2 CAPLUS
CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][(2,4,6-trichlorophenoxy)acetyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 211114-81-7 CAPLUS
CN Benzenepropanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-3,4-dichloro-N-[(2S,3S)-2-hydroxy-4-phenyl-3-[[2-(2,4,5-trichlorophenoxy)acetyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211114-83-9 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[(2-chloro-4-nitrobenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-84-0 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-chloro-4-nitrobenzoyl)amino]-2-hydroxy-4-phenylbutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-85-1 CAPLUS


CN 2H-Isoindole-2-propanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 211114-86-2 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxopropyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 211114-87-3 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211114-88-4 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][(2,4,6-trichlorophenoxy)acetyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-89-5 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3-(1,3-benzodioxol-5-yl)-1-oxopropyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-90-8 CAPLUS

CN Benzamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][(2,4,6-trichlorophenoxy)acetyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-chloro-3,4-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211115-00-3 CAPLUS

CN 1,3-Benzodioxole-5-propanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-04-1 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[2-(5-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-05-2 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N=[(2S,3S)-3-[[3,5-dimethoxy-4-(phenylmethoxy)benzoyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-06-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3,5-dimethoxy-4-(phenylmethoxy)benzoyl]amino]-2-hydroxy-4-phenylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-07-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3-(3-chlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-08-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[[(3-chlorophenyl)amino]acetyl]amino]-2-hydroxy-4-phenylbutyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-09-6 CAPLUS

CN 4-Piperidinecarboxamide, N-[(2S,3S)-3-[[[3,5-dimethoxy-4-(phenylmethoxy)benzoyl]amino]acetyl]amino]-2-hydroxy-4-phenylbutyl]-N-[2-(4-methoxyphenyl)ethyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-10-9 CAPLUS

CN 4-Piperidinecarboxamide, N-[(2S,3S)-3-[[3,5-dimethoxy-4-(phenylmethoxy)benzoyl]amino]-2-hydroxy-4-phenylbutyl]-N-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-11-0 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3-chlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-12-1 CAPLUS

CN 4-Piperidinecarboxamide, N-[(2S,3S)-3-[[3-chlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-N-[2-(4-methoxyphenyl)ethyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227031-13-2 CAPLUS

CN 4-Piperidinecarboxamide, N-[(2S,3S)-3-[[[(3-chlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-N-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 296780-76-2 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-[(2S,3S)-3-[[[(2E)-3-(2,6-dichlorophenyl)-1-oxo-2-propenyl]amino]-2-hydroxy-4-phenylbutyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 296780-77-3 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N-[(2S,3S)-3-[(2,5-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 296780-78-4 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N-[(2S,3S)-3-[(2E)-3-(2,6-dichlorophenyl)-1-oxo-2-propenyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 296780-79-5 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N-[(2S,3S)-3-[(2-chloro-3,4-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 296780-80-8 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N-[(2S,3S)-3-[[3,4-dichlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 296780-81-9 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[(1S,2S)-3-[[[1,1'-biphenyl]-4-ylacetyl][2-(2,4-dichlorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 296780-82-0 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(4-chlorophenyl)ethyl]-1,3-dihydro-N-[(2S,3S)-2-hydroxy-4-phenyl-3-[[2-(4,5-trichlorophenoxy)acetyl]amino]butyl]-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 296780-83-1 CAPLUS

CN Benzamide, 4-benzoyl-N-[(1S,2S)-3-[[2-(2,6-dichlorophenyl)-1-oxo-2-propenyl][1-(phenylmethyl)-4-piperidinyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 296780-84-2 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N-[(2S,3S)-3-[(3-chlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 296780-85-3 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N-[(2S,3S)-2-hydroxy-4-phenyl-3-[(2,4,5-trichlorophenoxy)acetyl]amino]butyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 296780-87-5 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N-[(2S,3S)-3-[(2,3-dichlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 296780-88-6 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[(1S,2S)-3-[[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]([1,1'-biphenyl]-4-ylacetyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 296780-89-7 CAPLUS


CN 1,3-Benzodioxole-5-propanamide, N-[(1S,2S)-3-[[[1,1'-biphenyl]-4-ylacetyl][1-(phenylmethyl)-4-piperidinyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 296780-90-0 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidiny]-N-[(2S,3S)-3-[[3,5-dimethoxy-4-(phenylmethoxy)benzoyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 296780-92-2 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[2-bromo-3-chlorophenoxy]acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 296780-93-3 CAPLUS
CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[3,4-dichlorophenoxy]acetyl][2-(2,4-dichlorophenyl)ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 296780-95-5 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[[(2E)-3-(2,6-dichlorophenyl)-1-oxo-2-propenyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 296780-96-6 CAPLUS

CN Benzamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][(2E)-3-(6-bromo-1,3-benzodioxol-5-yl)-1-oxo-2-propenyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-chloro-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 296780-98-8 CAPLUS

CN Benzamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][(2E)-3-(2,6-dichlorophenyl)-1-oxo-2-propenyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-chloro-3,4-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry:

Double bond geometry as shown.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:608584 CAPLUS

DN 133:187987

TI Methods using pyrimidine-based nucleosides for treatment of mitochondrial disorders

IN Naviaux, Robert K.

PA The Regents of the University of California, USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050043	A1	20000831	WO 2000-US4663	20000223
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2000008447 A 20020115 US 1999-121588PP 19990223
BR 2000-8447 20000223

US 1999-121588PP 19990223
WO 2000-US4663 W 20000223

EP 1171137 A1 20020116 EP 2000-910321 20000223

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

US 1999-121588PP 19990223

WO 2000-US4663 W 20000223

OS MARPAT 133:187987

AB Methods are provided for the treatment of mitochondrial disorders. The methods include the administration of a pyrimidine-based nucleoside, e.g. triacetyluridine. Also provided are methods of reducing or eliminating symptoms assocd. with mitochondrial disorders. Mitochondrial disorders particularly appropriate for treatment include those attributable to a deficiency of one or more pyrimidines.


IT 127779-20-8, Saquinavir 159989-64-7, Nelfinavir

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(pyrimidine-based nucleoside for treatment of mitochondrial disorder)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[1,1-dimethylethyl]amino]carbonyl]octahydro-2(1H)-isoquinoliny]l]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinoliny]lcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159989-64-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:608551 CAPLUS

DN 133:213151

TI Pharmaceutical compositions and methods for improved delivery of
hydrophobic therapeutic agents

IN Patel, Manesh V.; Chen, Feng-Jing

PA Lipocine, Inc., USA

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000050007	A1	20000831	WO 2000-US165	20000105
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6294192	B1	20010925	US 1999-258654 A	19990226
EP 1158959	A1	20011205	US 1999-258654	19990226
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		EP 2000-901394	20000105
			US 1999-258654 A	19990226
			WO 2000-US165 W	20000105
US 2002012680	A1	20020131	US 2001-898553	20010702
US 6451339	B2	20020917		

US 1999-258654 A119990226

AB The present invention relates to triglyceride-free pharmaceutical compns. for delivery of hydrophobic therapeutic agents. Compns. of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon diln. with an aq. solvent, the compn. forms a clear, aq. dispersion of the surfactants contg. the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compns. A pharmaceutical compn. contained cyclosporin 0.14, Cremophor RH-40 0.41, Arlacell186 0.29, sodium taurocholate 0.26, and propylene glycol 0.46 mg.


IT 127779-20-8, Saquinavir 159989-64-7, Nelfinavir

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-
dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-
(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 159989-64-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-
hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-,
(3S,4aS,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:573515 CAPLUS

DN 133:182970

TI Matrix controlled release device for a low-solubility drug

IN Appel, Leah Elizabeth; Friesen, Dwayne Thomas; Curatolo, William John;
Nightingale, James Alan Schriver; Thombre, Avinash Govind

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1027887	A2	20000816	EP 2000-300546	20000126
	EP 1027887	A3	20010228		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2000229888	A2	20000822	US 1999-119400PP	19990210
				JP 2000-33446	20000210
				US 1999-119400PP	19990210
	BR 2000000359	A	20010814	BR 2000-359	20000210
				US 1999-119400PP	19990210
AB	Disclosed are a controlled release dosage form for a low soly. drug that is a spray-dried or spray-coated amorphous solid dispersion of the drug in an ionizable cellulosic polymer matrix that is in turn incorporated into a secondary erodible polymeric matrix and a method of treating a disease or disorder comprising administering such a dosage form. A batch of solid dispersion was prepd. by spray-drying a soln. contg. drug 5-chloro-1H-indole-2-carboxylic acid [(1S-benzyl-3-(3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide (water soly. 80 .mu.g/mL) in acetone together with hydroxypropyl Me cellulose acetate succinate. The resulting solid dispersion was mixed with hydroxypropyl Me cellulose, lactose, and Mg stearate. The mixt. was finally compressed to give tablets.				
IT	186392-65-4				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cellulosic polymer and pH-sensitive polymer matrixes for solid dispersion of low-soly. drugs)				
RN	186392-65-4 CAPLUS				
CN	1H-Indole-2-carboxamide, 5-chloro-N-[(1S,2R)-3-[(3R,4S)-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L27 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:241263 CAPLUS
 DN 132:279548
 TI Preparation of tetrapeptide thiomethyl-, aminomethyl-, and sulfonamidomethyl-ketone derivs. as caspase inhibitors useful for treatment of apoptosis
 IN Lee, Dennis
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000020440	A1	20000413	WO 1999-US23271	19991006
	W: CA, JP, US				

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

US 1998-103428PP 19981006
EP 1129108 A1 20010905 EP 1999-953073 19991006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

US 1998-103428PP 19981006
WO 1999-US23271W 19991006

OS MARPAT 132:279548

AB This invention discloses novel compds. R1Z-AA1-AA2-AA3-NHCH(CH2CO2H)COCH2XR2 [I; R1 = alkyl, alkylaryl, aryl; Z = CO, SO2, NHCO; AA1, AA2, AA3 = (independently) a naturally occurring amino acid; X = S, O, N; R2 = alkyl, alkylaryl, aryl when X is sulfur or Y-R3 when X is nitrogen; Y = SO2, CO; R3 = (undefined) e.g. Me, Ph], their pharmaceutical compns., and the novel inhibition of caspases (no data) for use in the treatment of apoptosis, and disease states caused by excessive or inappropriate cell death. Thus, H2NCH(CH2CO2Bu-t)CHOHCH2N3 (prepn. given) was coupled to tripeptide Ac-Asp(OBu-t)-Glu(OBu-t)-Val-OH to give the tetrapeptide azidomethyl alc. The azidomethyl alc. was reduced to the aminomethyl alc. and reacted benzoyl chloride to give Ac-Asp(OBu-t)-Glu(OBu-t)-Val-NHCH(CH2CO2Bu-t)CHOHCH2NHCOPh which was oxidized to the ketone and deprotected with TFA to give Ac-Asp-Glu-Val-NHCH(CH2CO2H)COCH2NHCOPh. Representative compds. of formula I were said to inhibit caspase 3 in vitro.


IT 263859-16-1P 263859-17-2P 263859-18-3P
263859-19-4P 263859-20-7P 263859-22-9P
263859-24-1P 263859-26-3P 263859-30-9P
263859-33-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of tetrapeptide thiomethyl-, aminomethyl-, and sulfonamidomethyl-ketone derivs. as caspase inhibitors useful for treatment of apoptosis)


RN 263859-16-1 CAPLUS

CN Pentanoic acid, 5-azido-3-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-hydroxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 263859-17-2 CAPLUS

CN Pentanoic acid, 3-amino-5-azido-4-hydroxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 263859-18-3 CAPLUS

CN Pentonic acid, 3-[(N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl)amino]-5-azido-2,3,5-trideoxy-, tris(1,1-dimethylethyl) ester (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 263859-19-4 CAPLUS

CN Pentonic acid, 3-[(N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl)amino]-5-amino-2,3,5-trideoxy-, tris(1,1-dimethylethyl) ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 263859-20-7 CAPLUS

CN Pentonic acid, 3-[(N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl)amino]-5-(benzoylamino)-2,3,5-trideoxy-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 263859-22-9 CAPLUS

CN Pentonic acid, 3-[(N-acetyl-L-α-aspartyl-L-α-glutamyl-L-valyl)amino]-2,3,5-trideoxy-5-[(1-oxo-3-phenylpropyl)amino]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 263859-24-1 CAPLUS

CN Pentonic acid, 3-[(N-acetyl-L-α-aspartyl-L-α-glutamyl-L-valyl)amino]-2,3,5-trideoxy-5-[(phenylsulfonyl)amino]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 263859-26-3 CAPLUS

CN Pentonic acid, 3-[(N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl)amino]-2,3,5-trideoxy-5-[(methylsulfonyl)amino]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 263859-30-9 CAPLUS

CN Pentonic acid, 5-[[[5-(acetylamino)-3-methyl-2-thienyl]sulfonyl]amino]-3-[(N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl)amino]-2,3,5-trideoxy-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 263859-33-2 CAPLUS

CN Pentonic acid, 3-[(N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl)amino]-5-[[[5-[(benzoylamino)methyl]-2-thienyl]sulfonyl]amino]-2,3,5-trideoxy-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:203350 CAPLUS

DN 132:329816

TI Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus

AU Bi, Xiaoning; Haque, Tasir S.; Zhou, Jun; Skillman, A. Geoffrey; Lin, Bin; Lee, Christine E.; Kuntz, Irwin D.; Ellman, Jonathan A.; Lynch, Gary

CS Departments of Anatomy and Neurobiology and Psychiatry and Human Behavior, University of California at Irvine, Irvine, CA, 92697-3800, USA

SO Journal of Neurochemistry (2000), 74(4), 1469-1477

CODEN: JONRA9; ISSN: 0022-3042

PB Lippincott Williams & Wilkins

DT Journal

LA English

AB Lysosomal disturbances may be a contributing factor to **Alzheimer's** disease. We used novel compds. to test if suppression of the lysosomal protease cathepsin D blocks prodn. of known precursors to neurofibrillary tangles. Partial lysosomal dysfunction was induced in cultured hippocampal slices with a selective inhibitor of cathepsins B and L. This led within 48 h to hyperphosphorylated tau protein fragments recognized by antibodies against human tangles. Potent nonpeptidic cathepsin D inhibitors developed using combinatorial chem. and structure-based design blocked prodn. of the fragments in a dose-dependent fashion. Threshold was in the submicromolar range, with higher concns. producing complete suppression. The effects were selective and not accompanied by pathophysiol. Comparable results were obtained with three structurally distinct inhibitors. These results support the hypothesis that cathepsin D links lysosomal dysfunction to the etiol. of **Alzheimer's** disease and suggest a new approach to treating the disease.

IT 267887-24-1 267887-25-2 267887-26-3


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cathepsin D inhibitors block formation of hyperphosphorylated tau fragments in hippocampus)

RN 267887-24-1 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxy-4-(3-phenoxyphenyl)butyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267887-25-2 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(3S)-3-[[2-bromo-3-chlorophenoxy]acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267887-26-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(3S)-3-[[3-chlorophenoxy]acetyl]amino]-2-hydroxy-4-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:161780 CAPLUS

DN 132:329423

TI Conformational Selection of Inhibitors and Substrates by Proteolytic Enzymes: Implications for Drug Design and Polypeptide Processing

AU Fairlie, David P.; Tyndall, Joel D. A.; Reid, Robert C.; Wong, Allan K.; Abbenante, Giovanni; Scanlon, Martin J.; March, Darren R.; Bergman, Douglas A.; Chai, Christina L. L.; Burkett, Brendan A.

CS Centre for Drug Design and Development, University of Queensland, Brisbane, 4072, Australia

SO Journal of Medicinal Chemistry (2000), 43(7), 1271-1281

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Inhibitors of proteolytic enzymes (proteases) are emerging as prospective treatments for diseases such as AIDS and viral infections, cancers, inflammatory disorders, and **Alzheimer's** disease. Generic approaches to the design of protease inhibitors are limited by the unpredictability of interactions between, and structural changes to, inhibitor and protease during binding. A computer anal. of superimposed crystal structures for 266 small mol. inhibitors bound to 48 proteases (16 aspartic, 17 serine, 8 cysteine, and 7 metallo) provides the first conclusive proof that inhibitors, including substrate analogs, commonly bind in an extended .beta.-strand conformation at the active sites of all these proteases. Representative superimposed structures are shown for (a) multiple inhibitors bound to a protease of each class, (b) single inhibitors each bound to multiple proteases, and (c) conformationally constrained inhibitors bound to proteases. Thus inhibitor/substrate conformation, rather than sequence/compn. alone, influences protease recognition, and this has profound implications for inhibitor design. This conclusion is supported by NMR, CD, and binding studies for HIV-1 protease inhibitors/substrates which, when preorganized in an extended conformation, have significantly higher protease affinity. Recognition is dependent upon conformational equil. since helical and turn peptide conformations are not processed by proteases. Conformational selection explains the resistance of folded/structured regions of proteins to proteolytic degrdn., the susceptibility of denatured proteins to processing, and the higher affinity of conformationally constrained 'extended' inhibitors/substrates for proteases. Other approaches to extended inhibitor conformations should similarly lead to high-affinity binding to a protease.

IT 171858-52-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(conformational selection of inhibitors and substrates by proteolytic enzymes)

RN 171858-52-9 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(8S,11S)-8-[(1S)-1-methylpropyl]-7,10-dioxo-2-oxa-6,9-diazabicyclo[11.2.2]heptadeca-13,15,16-trien-11-yl]amino]-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L27 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 1999:717887 CAPLUS
DN 131:332307
TI Kynostatin and 17.β-estradiol prevent the apoptotic death of human neuroblastoma cells exposed to HIV-1 protease
AU Hawkins, Vivian; Shen, Qian; Chiueh, Chuang Chin
CS Howard Hughes Medical Institute, Montgomery Country Public School, Bethesda, MD, USA
SO Journal of Biomedical Science (Basel) (1999), 6(6), 433-438
CODEN: JBCIEA; ISSN: 1021-7770
PB S. Karger AG
DT Journal
LA English
AB A significant no. of adult male patients with acquired immunodeficiency syndrome develop cerebral atrophy and progressive brain disorders such as dementia complex and neuropsychiatric problems. Upon entering the brain via activated macrophages or microglia, the human immunodeficiency type 1 virus (HIV-1) may produce cytotoxic factors such as HIV-1 envelope protein (gp120) and protease. Owing to significant proteolysis of nonviral proteins, the protease derived from HIV-1 may be detrimental to brain cells and neurons. The results revealed that HIV-1 protease, at nanomolar concns., was as potent as gp120 in causing neurotoxicity in human neuroblastoma neurotypic SH-SY5Y cells. As shown by the Oncor Apop Tag staining procedure, HIV-1 protease increased the no. of apoptotic cells over the serum-free controls. Moreover, HIV-1 protease-induced neurotoxicity was blocked by a selective protease inhibitor, kynostatin (KNI-272). Antioxidants such as 17.β-estradiol, melatonin, and S-nitrosoglutathione also prevented protease-induced neurotoxicity. These findings indicate that oxidative proteolysis may mediate HIV-1 protease-induced apoptosis and the degeneration of neurons and other brain

cells. Centrally active protease inhibitors and antioxidants may play an important role in preventing cerebral atrophy and assocd. dementia complex caused by HIV-1.

IT 147318-81-8, Kynostatin


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(kynostatin and 17.beta.-estradiol prevent apoptosis of neuroblastoma cells exposed to HIV-1 protease)

RN 147318-81-8 CAPLUS

CN 4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[(2S,3S)-2-hydroxy-3-[[[(2R)-2-[[[5-isoquinolinyloxy)acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1999:548460 CAPLUS

DN 131:280972

TI Role of p-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

AU Polli, Joseph W.; Jarrett, Jeanne L.; Studenberg, Scott D.; Humphreys, Joan E.; Dennis, Steven W.; Brouwer, Kenneth R.; Woolley, Joseph L.

CS Division of Bioanalysis and Drug Metabolism Glaxo Wellcome, Inc., Research Triangle Park, NC, 27709, USA

SO Pharmaceutical Research (1999), 16(8), 1206-1212

CODEN: PHREEB; ISSN: 0724-8741

PB Kluwer Academic/Plenum Publishers

DT Journal

LA English

AB Purpose: to det. the role of P-glycoprotein (Pgp) on the CNS penetration of the HIV protease inhibitor (PI) amprenavir (141 W94) and to test the hypothesis that co-administration of a second HIV PI (ritonavir) could enhance amprenavir's brain penetration in vivo. Methods: Pgp-mediated efflux was investigated in vitro with Caco-2 cells and in vivo by whole-body autoradiog. (WBA). "Genetic" mdrla/1b double knockout mice, "chem." Pgp knockout mice generated by administration of the Pgp inhibitor GF120918, and mice pretreated with ritonavir were used in WBA studies to investigate the effects of Pgp modulation on the CNS penetration of amprenavir. Results: amprenavir, indinavir, ritonavir, and saquinavir had 2-to 23-fold higher transport rates from the basolateral to apical direction than from the apical to basolateral direction across Caco-2 monolayers. Incubation with GF120918 negated this difference, suggesting that the efflux was Pgp-mediated. WBA studies demonstrated a 13- and 27-fold increase in the brain and a 3.3-fold increase in the CSF concns.

of amprenavir in mice pretreated with GF120918 and in mdrla/1b double knockout mice. In contrast, pretreatment with ritonavir did not alter the CNS exposure of amprenavir. Conclusions: these results provide evidence that amprenavir and other HIV PIs are Pgp substrates and that co-administration of a specific Pgp inhibitor will enhance amprenavir's CNS penetration in vivo. These results will have an important therapeutic impact in the treatment of AIDS dementia.

IT 127779-20-8, Saquinavir 161814-49-9, Amprenavir


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(CNS disposition of HIV protease inhibitors: P-glycoprotein role and pharmacokinetic interactions)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161814-49-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1999:256246 CAPLUS

DN 131:53626

TI HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833

AU Drewe, Jurgen; Gutmann, Heike; Fricker, Gert; Torok, Michael; Beglinger, Christoph; Huwyler, Jorg

CS Department of Research and Department of Clinical Pharmacology, University Hospital, Basel, CH-4031, Switz.

SO Biochemical Pharmacology (1999), 57(10), 1147-1152
CODEN: BCPA6; ISSN: 0006-2952

PB Elsevier Science Inc.
DT Journal
LA English


AB The effect of P-glycoprotein inhibition on the uptake of the HIV type 1 protease inhibitor saquinavir into brain capillary endothelial cells was studied using porcine primary brain capillary endothelial cell monolayers as an in vitro test system. As confirmed by polymerase chain reaction and Western blot anal., this system functionally expressed class I P-glycoprotein (pgp1A). P-Glycoprotein isoforms pgp1B or pgp1D could not be detected. The uptake of saquinavir into endothelial cells could be described as the result of a diffusional term of uptake and an oppositely directed saturable extrusion process. Net uptake of saquinavir into cultured brain endothelial cells could be increased significantly up to 2-fold by SDZ PSC 833 in a dose-dependent manner, with an IC50 of 1.13 .mu.M. In addn., the HIV protease inhibitor ritonavir inhibited p-glycoprotein-mediated extrusion of saquinavir with an IC50 of 0.2 .mu.M, indicating a high affinity of ritonavir for p-glycoprotein. In conclusion, we showed that the HIV protease inhibitor ritonavir is a more potent inhibitor of P-glycoprotein than the multidrug resistance (MDR)-reversing agent SDZ PSC 833. The inclusion of this drug in combination regimens may greatly facilitate brain uptake of HIV protease inhibitors, which is esp. important in patients suffering from AIDS dementia complex.

IT 127779-20-8, Saquinavir
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HIV protease inhibitor ritonavir vs. P-glycoprotein inhibitor SDZPSC833 effects on saquinavir brain uptake)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[1,1-dimethylethyl]amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 1999:136704 CAPLUS
DN 131:137
TI Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy
AU Moyle, G. J.; Sadler, M.; Buss, N.
CS HIV/Genito-Urinary Medicine Department, Chelsea and Westminster Hospital, London, UK

SO Clinical Infectious Diseases (1999), 28(2), 403-404
CODEN: CIDIEL; ISSN: 1058-4838
PB University of Chicago Press
DT Journal
LA English
AB The study examd. the saquinavir plasma and cerebrospinal fluid concns. in patients with HIV infection receiving combination antiretroviral therapy.
IT 127779-20-8, Saquinavir
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (saquinavir plasma and cerebrospinal fluid concns. in patients receiving combination antiretroviral therapy)
RN 127779-20-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 1999:108939 CAPLUS
DN 130:246258
TI Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS **dementia** complex
AU Aweeka, Francesca; Jayewardene, Anura; Staprans, Silvija; Bellibas, S. Eralp; Kearney, Brian; Lizak, Patricia; Novakovic-Agopian, Tatjana; Price, Richard W.
CS Department of Clinical Pharmacy, University of California, San Francisco, CA, 94143-0622, USA
SO Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology (1999), 20(1), 39-43
CODEN: JDSRET; ISSN: 1077-9450
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB To assess the penetration of the HIV-1 protease inhibitor, nelfinavir, into cerebrospinal fluid (CSF). Nelfinavir, a commonly used HIV-1 protease inhibitor (PI), is highly effective for reducing plasma viral load. It is deployed clin. in combination with other antiretroviral agents, including nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs). Despite its potency based on plasma HIV-1 RNA results, its effectiveness in reducing HIV-1 RNA levels (i.e., viral load) in the central nervous system (CNS) is less certain. We sampled the CSF as a surrogate for brain because this fluid also is sepd. from the blood by a barrier to free diffusion, the blood-CSF barrier (BCB), which

shares properties with the blood-brain barrier (BBB).—These studies of nelfinavir CSF pharmacokinetics exploited the multiple CSF samples derived from individual study subjects who were enrolled in studies the primary objective of which was to compare viral kinetics in CSF and blood in response to antiviral therapy. Six study subjects, four with and two without AIDS dementia complex, underwent multiple lumbar punctures (LP). Intervals of CSF sampling after drug dosing were varied (from 0.48 h to 10.3 h after nelfinavir administration) to quantitate nelfinavir concns. throughout the steady-state dosing interval. In four study subjects, CSF sampling was accompanied by assessment of nelfinavir levels in plasma before and after LP, whereas in the other two subjects, a single plasma sample was obtained before or after the LP. In total, 25 CSF samples were analyzed. Nelfinavir concns. in CSF and plasma were detd. using an high-performance liq. chromatog. (HPLC) method with a limit of quantitation of 25 and 50 ng/mL, resp. Plasma concns. before and after LP averaged 2420.+-.1365 ng/mL and 2528.+-.1132 ng/mL, resp. Nelfinavir was not detected in any of the CSF samples and levels >25 ng/mL were not present in the CSF. Thus, std. therapy with nelfinavir does not result in CSF drug concns. at or exceeding the IC95 level for most HIV-1 isolates. However, study subjects with high CSF viral loads experienced a marked redn. in the context of the combination-drug regimen including nelfinavir with two subjects showing a comparable CSF response with that in plasma. Nelfinavir does not appreciably penetrate into the CSF. The clin. importance of this observation is not certain, in that in four study subjects who initiated nelfinavir in combination with other antiretroviral therapy, a comparable degree of viral suppression was obtained in both the CSF and the blood when sampled 4 wk or later after initiating therapy.

IT 159989-64-7, Nelfinavir


RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)

(failure to detect nelfinavir in cerebrospinal fluid of HIV-1-infected humans with and without AIDS **dementia** complex)

RN 159989-64-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1998:785791 CAPLUS

DN 130:29253

TI Antiviral combinations containing the carbocyclic nucleoside 1592U89

IN St. Clair, Martha Heider; Barry, David Walter

PA Glaxo Group Ltd., UK
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9852571	A1	19981126	WO 1998-EP2837	19980514
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			GB 1997-9945	A 19970517
			GB 1997-19866	A 19970919
AU 9880172	A1	19981211	AU 1998-80172	19980514
			GB 1997-9945	A 19970517
			GB 1997-19866	A 19970919
			WO 1998-EP2837	W 19980514
EP 1019056	A1	20000719	EP 1998-928261	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			GB 1997-9945	A 19970517
			GB 1997-19866	A 19970919
			WO 1998-EP2837	W 19980514
BR 9809124	A	20000801	BR 1998-9124	19980514
			GB 1997-9945	A 19970517
			GB 1997-19866	A 19970919
			WO 1998-EP2837	W 19980514
GB 2348202	A1	20000927	GB 2000-10222	19980514
GB 2348202	B2	20010808		
			GB 1997-9945	A 19970517
			GB 1999-26839	A319980514
JP 2000327679	A2	20001128	JP 2000-138178	19980514
			GB 1997-9945	A 19970517
			JP 1998-549910	A319980514
JP 2001525840	T2	20011211	JP 1998-549912	19980514
			GB 1997-9945	A 19970517
			GB 1997-19866	A 19970919
			WO 1998-EP2837	W 19980514
NO 9905621	A	20000114	NO 1999-5621	19991116
			GB 1997-9945	A 19970517
			GB 1997-19866	A 19970919
			WO 1998-EP2837	W 19980514

PATENT FAMILY INFORMATION:

FAN 1998:785790

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9852570	A1	19981126	WO 1998-EP2836	19980514
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			GB 1997-9945	A 19970517
			GB 1997-19883	A 19970919

AU 9879123	A1	19981211	AU 1998-79123	19980514
			GB 1997-9945	A 19970517
			GB 1997-19883	A 19970919
			WO 1998-EP2836	W 19980514
EP 979082	A1	20000216	EP 1998-929309	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			GB 1997-9945	A 19970517
			GB 1997-19883	A 19970919
			WO 1998-EP2836	W 19980514
BR 9809127	A	20000801	BR 1998-9127	19980514
			GB 1997-9945	A 19970517
			GB 1997-19883	A 19970919
			WO 1998-EP2836	W 19980514
GB 2348202	A1	20000927	GB 2000-10222	19980514
GB 2348202	B2	20010808		
			GB 1997-9945	A 19970517
			GB 1999-26839	A319980514
JP 2000327679	A2	20001128	JP 2000-138178	19980514
			GB 1997-9945	A 19970517
			JP 1998-549910	A319980514
JP 2001525839	T2	20011211	JP 1998-549911	19980514
			GB 1997-9945	A 19970517
			GB 1997-19883	A 19970919
			WO 1998-EP2836	W 19980514
NO 9905620	A	20000114	NO 1999-5620	19991116
			GB 1997-9945	A 19970517
			GB 1997-19883	A 19970919
			WO 1998-EP2836	W 19980514
FAN 1998:789152				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
PI WO 9852949	A1	19981126	WO 1998-EP2835	19980514
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			GB 1997-9945	A 19970517
AU 9877655	A1	19981211	AU 1998-77655	19980514
AU 739953	B2	20011025		
			GB 1997-9945	A 19970517
			WO 1998-EP2835	W 19980514
ZA 9804083	A	19991115	ZA 1998-4083	19980514
			GB 1997-9945	A 19970517
ZA 9804085	A	19991115	ZA 1998-4085	19980514
			GB 1997-9945	A 19970517
GB 2340491	A1	20000223	GB 1999-26839	19980514
GB 2340491	B2	20001018		
			GB 1997-9945	A 19970517
			WO 1998-EP2835	W 19980514
EP 983271	A1	20000308	EP 1998-925601	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			GB 1997-9945	A 19970517
			WO 1998-EP2835	W 19980514
BR 9809126	A	20000801	BR 1998-9126	19980514
			GB 1997-9945	A 19970517
			WO 1998-EP2835	W 19980514
GB 2348202	A1	20000927	GB 2000-10222	19980514

GB 2348202 B2 20010808

JP 2000514096 T2 20001024
JP 3150711 B2 20010326

JP 2000327679 A2 20001128

NO 9905622 A 20000114

US 6294540 B1 20010925

GB 1997-9945 A 19970517
GB 1999-26839 A319980514
JP 1998-549910 19980514GB 1997-9945 A 19970517
WO 1998-EP2835 W 19980514
JP 2000-138178 19980514
GB 1997-9945 A 19970517
JP 1998-549910 A319980514
NO 1999-5622 19991116
GB 1997-9945 A 19970517
WO 1998-EP2835 W 19980514
US 1999-423982 19991201
GB 1997-9945 A 19970517
WO 1998-EP2835 W 19980514

AB The present invention relates to therapeutic combinations of (-)-(1S, 4R)-4-[2-amino-6- (cyclopropylamino)-9H-purin-9-yl] -2-cyclopentene-1-methanol (1592U89) and HIV protease inhibitors which have anti-HIV activity. The present invention is also concerned with pharmaceutical compns. contg. said combinations and their use in the treatment of HIV infections.


IT 127779-20-8, Saquinavir 159989-64-7, Nelfinavir

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (antiviral combinations contg. the carbocyclic nucleoside 1592U89)

RN 127779-20-8 CAPLUS

CN Butanediamide, N1-[(1S, 2R)-3-[(3S, 4aS, 8aS)-3-[[(1, 1-dimethylethyl) amino] carbonyl] octahydro-2 (1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl) propyl]-2-[(2-quinolinyl carbonyl) amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159989-64-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl) decahydro-2-[(2R, 3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl) amino]-4-(phenylthio) butyl]-, (3S, 4aS, 8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 1998:543069 CAPLUS
DN 129:161551
TI Preparation of nanomolar, non-peptide heterocycle-containing inhibitors of
cathepsin D
IN Kick, Ellen K.; Ellman, Jonathan A.; Kuntz, Irwin D.; Lee, Christina E.;
Liu, Guangcheng; Roe, Diana C.; Skillman, A. Geoffrey
PA The Regents of the University of California, USA
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833795	A1	19980806	WO 1998-US2199	19980203
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9862686	A1	19980825	US 1997-36903P P	19970204
AU 749281	B2	20020620	AU 1998-62686	19980203
US 1997-36903P P 19970204 WO 1998-US2199 W 19980203				
EP 958293	A1	19991124	EP 1998-904934	19980203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 1997-36903P P 19970204 WO 1998-US2199 W 19980203				
US 6150416	A	20001121	US 1998-18226	19980203
US 1997-36903P P 19970204				
JP 2001510474	T2	20010731	JP 1998-533236	19980203
US 1997-36903P P 19970204 WO 1998-US2199 W 19980203				

OS MARPAT 129:161551
GI



I

AB The title compds. I [R1, R2 and R3 = alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl, substituted aryloxyalkyl, heteroaryl, substituted heteroaryl, etc.; R5 and R6 are independently selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl, or R5 and R6 and the carbons to which they are bound join to form an optionally substituted 9- or 10-ring atom carbocyclic or heterocyclic fused ring system] are prepd. The present invention provides non-peptide cathepsin D binding compds. and methods for using such compds. in the detection, labeling and inhibition of cathepsin D. Compds. of this invention in vitro showed IC50 values of 14.+-.2 nM to 64.+-.6 nM against cathepsin D.

IT 192069-75-3P 192069-78-6P 192069-80-0P
 192069-83-3P 192069-84-4P 192069-91-3P
 192069-95-7P 192069-96-8P 192069-98-0P
 192069-99-1P 192070-00-1P 211114-70-4P
 211114-71-5P 211114-72-6P 211114-73-7P
 211114-74-8P 211114-75-9P 211114-76-0P
 211114-77-1P 211114-78-2P 211114-79-3P
 211114-80-6P 211114-81-7P 211114-82-8P
 211114-83-9P 211114-84-0P 211114-85-1P
 211114-86-2P 211114-87-3P 211114-88-4P
 211114-89-5P 211114-90-8P 211114-91-9P
 211114-92-0P 211114-94-2P 211114-99-7P
 211115-00-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nanomolar, non-peptide inhibitors of cathepsin D)

RN 192069-75-3 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-1,3-dihydro-N-[(2S,3S)-2-hydroxy-4-phenyl-3-[[2,4,5-trichlorophenoxy]acetyl]amino]butyl]-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-78-6 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[(2-chloro-3,4-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-80-0 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-83-3 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-84-4 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-91-3 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3,4-dichlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-95-7 CAPLUS


CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[[3,4-dichlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192069-96-8 CAPLUS
 CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[(2,4-dichlorophenoxy) acetyl] amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192069-98-0 CAPLUS
 CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[(3-chlorophenoxy) acetyl] amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192069-99-1 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192070-00-1 CAPLUS

CN 2H-Isoindole-2-propanamide, 1,3-dihydro-N-[(2S,3S)-2-hydroxy-4-phenyl-3-[[[(2,4,5-trichlorophenoxy)acetyl]amino]butyl]-N-[2-(4-methylphenyl)ethyl]-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-70-4 CAPLUS

CN Benzenepropanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-3,4-dichloro-N-[(2S,3S)-3-[(2-chloro-3,4-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-71-5 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-chloro-3,4-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-72-6 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[4-chlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-73-7 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxy-4-(4-phenoxyphenyl)butyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-74-8 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxy-4-(2-naphthalenyl)butyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-75-9 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-4-[1,1'-biphenyl]-4-yl-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxybutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-76-0 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-4-(4-bromophenyl)-2-hydroxybutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-77-1 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][(2,4,6-trichlorophenoxy)acetyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-78-2 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][(2,4,6-trichlorophenoxy)acetyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-79-3 CAPLUS

CN 3(2H)-Benzoxazolepropanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-80-6 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3-(2,6-dichlorophenyl)-1-oxo-2-propenyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 211114-81-7 CAPLUS


CN Benzenepropanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-3,4-dichloro-N-[(2S,3S)-2-hydroxy-4-phenyl-3-[[[2,4,5-trichlorophenoxy]acetyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 211114-82-8 CAPLUS
CN Benzamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(6-bromo-1,3-benzodioxol-5-yl)-1-oxo-2-propenyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-chloro-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 211114-83-9 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[(2-chloro-4-nitrobenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211114-84-0 CAPLUS
CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-chloro-4-nitrobenzoyl)amino]-2-hydroxy-4-phenylbutyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-85-1 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-86-2 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxopropyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-87-3 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-88-4 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(1S,2S)-3-[[2-(2,4-dichlorophenyl)ethyl][(2,4,6-trichlorophenoxy)acetyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-89-5 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[[3-(1,3-benzodioxol-5-yl)-1-oxopropyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-90-8 CAPLUS

CN Benzamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][(2,4,6-trichlorophenoxy)acetyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-chloro-3,4-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-91-9 CAPLUS

CN Benzamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(2,6-dichlorophenyl)-1-oxo-2-propenyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-chloro-3,4-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 211114-92-0 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-[(2S,3S)-3-[(3,4-dimethoxybenzoyl)amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-94-2 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[(2S,3S)-3-[(2-bromo-4,5-dimethoxybenzoyl)amino]-2-hydroxy-4-(3-phenoxyphenyl)butyl]-N-[2-(2,4-dichlorophenyl)ethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211114-99-7 CAPLUS

CN 2H-Isoindole-2-propanamide, N-[2-(2,4-dichlorophenyl)ethyl]-N-[(2S,3S)-3-[[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxopropyl]amino]-2-hydroxy-4-phenylbutyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211115-00-3 CAPLUS

CN 1,3-Benzodioxole-5-propanamide, N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(3,4-dichlorophenyl)-1-oxopropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1998:251155 CAPLUS

DN 128:308302

TI Sulfonamide interleukin-1.beta. converting enzyme inhibitors

IN Albrecht, Hans P.; Allen, Hamish John; Brady, Kenneth Dale; Harter, William Glen; Kostlan, Catherine Rose; Roth, Bruce David; Walker, Nigel
PA Warner-Lambert Company, USA; Albrecht, Hans P.; Allen, Hamish John; Brady, Kenneth Dale; Harter, William Glen; Kostlan, Catherine Rose; Roth, Bruce David; Walker, Nigel

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9816505	A1	19980423	WO 1997-US18396	19971009
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9747538	A1	19980511	US 1996-28313P P	19961011
	AU 736694	B2	20010802	AU 1997-47538	19971009
				US 1996-28313P P	19961011
				WO 1997-US18396W	19971009
EP	946502	A1	19991006	EP 1997-910074	19971009
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1996-28313P P	19961011
				WO 1997-US18396W	19971009
BR	9712987	A	20000418	BR 1997-12987	19971009
				US 1996-28313P P	19961011
				WO 1997-US18396W	19971009
JP	2001508404	T2	20010626	JP 1998-518478	19971009
				US 1996-28313P P	19961011
				WO 1997-US18396W	19971009
NO	9901674	A	19990412	NO 1999-1674	19990409
				US 1996-28313P P	19961011
				WO 1997-US18396W	19971009
US	6316415	B1	20011113	US 1999-284422	19990409
				US 1996-28313P P	19961011
				WO 1997-US18396W	19971009
KR	2000049047	A	20000725	KR 1999-703116	19990410

US 1996-28313P P 19961011

OS MARPAT 128:308302

AB The title compds. $R_1NHC(CH_2CO_2H)COCH_2NHSO_2R_2$ [$R_1 = R_3COAm$, R_4SO_2Am , R_5R_6NCOAm , etc.; $R_2 = (CH_2)_nZ$; $R_3, R_5, R_6 = H$, C1-6 alkyl, $(CH_2)_n$ -aryl, $(CH_2)_n$ -heteroaryl; $R_4 = C1-6$ alkyl, $(CH_2)_n$ -aryl, $(CH_2)_n$ -heteroaryl; $A =$ alanine, leucine, isoleucine, etc.; $Z =$ aryl, heteroaryl, cycloalkyl, etc.; $m = 0, 1, 2, 3$; $n = 0-6$] are prepd. A pharmaceutically acceptable compn. contg. the compds. is useful for treatment of stroke, reperfusion injury, **Alzheimer's** disease, shigellosis, inflammatory diseases, and septic shock. Thus, 3-benzoyloxycarbonylamino-4-oxo-5(2-phenylethane-sulfonylamino)pentanoic acid was prepd. and showed ICE IC₅₀ 73 . μ M, and Ich-2 IC₅₀ (caspase 4) 96 . μ M.


IT 206198-23-4P 206198-24-5P 206198-25-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(sulfonamide interleukin-1. beta. converting enzyme inhibitors)

RN 206198-23-4 CAPLUS

CN D-glycero-Pentonic acid, 2,3,5-trideoxy-3-[[[3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)acetyl]amino]-5-nitro-, 1,1-dimethylethyl ester, (4.xi.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206198-24-5 CAPLUS

CN D-glycero-Pentonic acid, 5-amino-2,3,5-trideoxy-3-[[[3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)acetyl]amino]-, 1,1-dimethylethyl ester, (4.xi.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206198-25-6 CAPLUS

CN D-glycero-Pentonic acid, 2,3,5-trideoxy-3-[[[3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)acetyl]amino]-5-[(phenylsulfonyl)amino]-, 1,1-dimethylethyl ester, (4.xi.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1998:42288 CAPLUS

DN 128:119660

TI Pharmaceuticals containing VX478, zidovudine and FTC and/or 3TC for HIV virus treatment

IN St. Clair, Martha Heider; Barry, David Walter

PA Glaxo Group Ltd., UK

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9749411	A1	19971231	WO 1997-EP3247	19970623
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2258956	AA	19971231	US 1996-20543P P	19960625
			US 1996-21027P P	19960702
			GB 1996-14022 A	19960704
			CA 1997-2258956	19970623
			US 1996-20543P P	19960625
			US 1996-21027P P	19960702
			GB 1996-14022 A	19960704
AU 9732627	A1	19980114	AU 1997-32627	19970623
AU 727983	B2	20010104		
			US 1996-20543P P	19960625
			US 1996-21027P P	19960702
			GB 1996-14022 A	19960704
BR 9709939	A	19990810	WO 1997-EP3247 W	19970623
			BR 1997-9939	19970623
			US 1996-20543P P	19960625
			US 1996-21027P P	19960702
			GB 1996-14022 A	19960704
			WO 1997-EP3247 W	19970623
EP 938321	A1	19990901	EP 1997-928263	19970623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			US 1996-20543P P	19960625
			US 1996-21027P P	19960702
			GB 1996-14022 A	19960704
CN 1228026	A	19990908	WO 1997-EP3247 W	19970623
			CN 1997-197357	19970623

			US 1996-20543P P 19960625
			US 1996-21027P P 19960702
JP 2000515852	T2	20001128	GB 1996-14022 A 19960704
			JP 1998-502320 19970623
			US 1996-20543P P 19960625
			US 1996-21027P P 19960702
			GB 1996-14022 A 19960704
TW 469132	B	20011221	WO 1997-EP3247 W 19970623
			TW 1997-86111193 19970805
			US 1996-20543P P 19960625
			US 1996-21027P P 19960702
NO 9806034	A	19990223	GB 1996-14022 A 19960704
			NO 1998-6034 19981222
			US 1996-20543P P 19960625
			US 1996-21027P P 19960702
			GB 1996-14022 A 19960704
KR 2000022226	A	20000425	WO 1997-EP3247 W 19970623
			KR 1998-710646 19981224
			US 1996-20543P P 19960625
			US 1996-21027P P 19960702
			GB 1996-14022 A 19960704


AB The present invention relates to therapeutic combinations of 3S-[3R*(1R*,2S*)-[3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid tetrahydro-3-furanyl ester (141W94), zidovudine and (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC)) which have anti-HIV activity. Pharmaceutical compns. contg. these combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors are also described. Tablets were prepd. from the drug combination 250, lactose 210, Povidone 15, sodium starch glycolate 20, and Mg stearate 5 mg/tablet. The antiviral activity of the combination drugs was demonstrated.

IT **161814-49-9**, 141W94
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals contg. VX478 and zidovudine and FTC and/or 3TC for HIV virus treatment)

RN 161814-49-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1998:42287 CAPLUS

DN 128:119659

TI Pharmaceuticals containing VX478, zidovudine and/or 1592U89 for use in the treatment of HIV virus

IN St. Clair, Martha Heider; Barry, David Walter

PA Glaxo Group Ltd., UK

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9749410	A1	19971231	WO 1997-EP3246	19970623
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1996-22178P P	19960625
				GB 1996-14024 A	19960704
	AU 9732626	A1	19980114	AU 1997-32626	19970623
	AU 723877	B2	20000907		
				US 1996-22178P P	19960625
				GB 1996-14024 A	19960704
				WO 1997-EP3246 W	19970623
	ZA 9705565	A	19981223	ZA 1997-5565	19970623
				US 1996-22178P P	19960625
	EP 910386	A1	19990428	EP 1997-928262	19970623
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1996-22178P P	19960625
				GB 1996-14024 A	19960704
				WO 1997-EP3246 W	19970623
	BR 9709951	A	19990810	BR 1997-9951	19970623
				US 1996-22178P P	19960625
				GB 1996-14024 A	19960704
				WO 1997-EP3246 W	19970623
	JP 2001509786	T2	20010724	JP 1998-502319	19970623
				GB 1996-14024 A	19960704
				WO 1997-EP3246 W	19970623
	CN 1306430	A	20010801	CN 1997-197356	19970623
				US 1996-22178P P	19960625
				GB 1996-14024 A	19960704
	NO 9806035	A	19990223	NO 1998-6035	19981222
				US 1996-22178P P	19960625
				GB 1996-14024 A	19960704
				WO 1997-EP3246 W	19970623
	KR 2000022225	A	20000425	KR 1998-710645	19981224
				US 1996-22178P P	19960625
				GB 1996-14024 A	19960704
AB	The present invention relates to therapeutic combinations of 3S-[3R*(1R*,2S*)-[3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid tetrahydro-3-furanyl ester (141W94), zidovudine and (1S,4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) which have anti-HIV activity. Pharmaceutical compns. contg. these combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors are also described. Tablets were prepd. from the drug combination 250, lactose 210, Povidone 15, sodium starch glycolate 20, and Mg stearate 5 mg/tablet. The antiviral activity of the combination drugs was demonstrated.				
IT	161814-49-9, 141W94				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological				


study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceuticals contg. VX478 and zidovudine and/or 1592U89 for treatment of HIV virus)

RN 161814-49-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1997:470087 CAPLUS

DN 127:76018

TI Treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC

IN Chaturvedi, Pravin Ramsewak

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9720554	A1	19970612	WO 1996-US19447	19961205
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9610139	A	19970617	US 1995-567199 A	19951205
				ZA 1996-10139	19961203
				US 1995-567199 A	19951205
	CA 2238471	AA	19970612	CA 1996-2238471	19961205
				US 1995-567199 A	19951205
	AU 9711486	A1	19970627	AU 1997-11486	19961205
	AU 722850	B2	20000810		
				US 1995-567199 A	19951205
				WO 1996-US19447W	19961205
	EP 866696	A1	19980930	EP 1996-942917	19961205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1995-567199 A	19951205
				WO 1996-US19447W	19961205
	CN 1203530	A	19981230	CN 1996-198816	19961205
				US 1995-567199 A	19951205
	BR 9611861	A	19990518	BR 1996-11861	19961205
				US 1995-567199 A	19951205

NO 9802556

A

19980604


WO 1996-US19447W 19961205

NO 1998-2556 19980604

US 1995-567199 A 19951205

WO 1996-US19447W 19961205

GI



I

AB Central nervous system (CNS) effects of HIV, particularly AIDS related dementia are treated with VX-478 (I) alone or in combination with AZT or 3TC.

IT **161814-49-9P**, VX-478


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC)

RN 161814-49-9 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **160232-13-3**


RL: RCT (Reactant); RACT (Reactant or reagent)

(treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC)

RN 160232-13-3 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **160231-69-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC)

RN 160231-69-6 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1995:810448 CAPLUS

DN 123:218429

TI Aspartyl proteinase inhibitor preparation, assay, and use for treatment of **Alzheimer's** Disease

IN Dovey, Harry F.; John, Varghese; Laguzza, Bennett C.; Lieberberg, Ivan M.; Little, Sheila P.; Sinha, Sukanto

PA Lilly, Eli, and Co., USA; Athena, Eli, and Co.

SO Can. Pat. Appl., 175 pp.

CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2129689	AA	19950210	CA 1994-2129689	19940808
				US 1993-104293	19930809
	ZA 9405719	A	19960201	ZA 1994-5719	19940801
				US 1993-104293	19930809
	EP 652009	A1	19950510	EP 1994-305833	19940805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			US 1993-104293	19930809
	AU 9468970	A1	19950216	AU 1994-68970	19940808
				US 1993-104293	19930809
	HU 71515	A2	19951228	HU 1994-2312	19940808
				US 1993-104293	19930809
	CN 1120040	A	19960410	CN 1994-109527	19940808
				US 1993-104293	19930809

OS MARPAT 123:218429


AB .beta.-Amyloid peptide (.beta.AP) prodn. in cell culture and in vivo is inhibited by administering aspartyl protease inhibitors, particularly inhibitors of proteases of cathepsin D. Useful aspartyl protease inhibitors can be selected in a two-step assay, where test compds. are first screened for aspartyl protease inhibition activity in vitro in noncellular assays. Those test compds. which are found to display protease inhibition activity are then tested in cellular assay for .beta.AP prodn. inhibition. Those test compds. which are capable of inhibiting intracellular B-amyloid prodn. may be incorporated in pharmaceutical compns.

IT 168172-23-4P 168394-47-6P 168394-48-7P
168394-50-1P

RL: ANT (Analyte); BAC (Biological activity or effector, except adverse);
 BSU (Biological study, unclassified); SPN (Synthetic preparation); THU
 (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (aspartyl proteinase inhibitor prepn., assay, and use for treatment of
Alzheimer's Disease)


RN 168172-23-4 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[2-hydroxy-3-
 [[2-methyl-5-[(1,2,3,4-tetrahydro-1-isoquinolinyl)carbonyl]benzoyl]amino]-
 4-phenylbutyl]- (9CI) (CA INDEX NAME)




RN 168394-47-6 CAPLUS

CN Butanediamide, N1-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-
 2(1H)-isoquinolinyl]-2-hydroxy-1-[(2-naphthalenylthio)methyl]propyl]-2-[(2-
 quinolinylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 168394-48-7 CAPLUS


CN Butanediamide, N1-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-
 2(1H)-isoquinolinyl]-2-hydroxy-1-[(phenylthio)methyl]propyl]-2-[(2-
 quinolinylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 168394-50-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N3-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octa-
 hydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-N1,4-

dimethyl-N1-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




IT 136522-17-3P 137431-05-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aspartyl proteinase inhibitor prepn., assay, and use for treatment of Alzheimer's Disease)

RN 136522-17-3 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(1,1-dimethylethyl)decahydro-, (3S,4aS,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 137431-05-1 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



FILE 'HOME' ENTERED AT 15:32:34 ON 26 SEP 2002

L Number	Hits	Search Text	DB	Time stamp
1	2040	(514/252.12,616,617").CCLS	USPAT	2003/09/20 12:03
2	1342	("544/358,398,402").CCLS	USPAT	2003/09/20 12:03
3	2040	((514/252.12,616,617").CCLS) and ((514/252.12,616,617").CCLS)	USPAT	2003/09/20 12:03
4	426	((514/252.12,616,617").CCLS) and ((514/252.12,616,617").CCLS)) and piperazine	USPAT	2003/09/20 12:04
5	84	((514/252.12,616,617").CCLS) and ((514/252.12,616,617").CCLS)) and piperazine) and Alzheimer	USPAT	2003/09/20 12:05

L Number	Hits	Search Text	DB	Time stamp
1	2040	(514/252.12,616,617").CCLS	USPAT	2003/09/20 12:03
2	1342	("544/358,398,402").CCLS	USPAT	2003/09/20 12:03
3	2040	((514/252.12,616,617").CCLS) and ((514/252.12,616,617").CCLS)	USPAT	2003/09/20 12:03
4	426	((514/252.12,616,617").CCLS) and ((514/252.12,616,617").CCLS)) and piperazine	USPAT	2003/09/20 12:04
5	84	((514/252.12,616,617").CCLS) and ((514/252.12,616,617").CCLS)) and piperazine) and Alzheimer	USPAT	2003/09/20 12:05



1

1